Heterocyclic compounds for treatment of epilepsy

Novel pyrimidine compounds with specific heterocyclic structures address the limitations of existing antiepileptic drugs by maintaining neuronal balance and offering a broader therapeutic spectrum, effectively treating various seizures with minimal side effects.

JP2024160219AActive Publication Date: 2024-11-13OTSUKA PHARM CO LTD
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2024106223
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-11-30
Filing Date
2024-07-01
Publication Date
2024-11-13
Estimated Expiration
2039-11-29

AI Technical Summary

Technical Problem

Existing antiepileptic drugs often disrupt the neuronal excitation-inhibition balance at higher doses, leading to side effects like movement disorders, and have a limited therapeutic spectrum, failing to adequately control seizures in 30% of epilepsy patients.

Method used

Development of novel pyrimidine compounds with specific heterocyclic structures that maintain the excitation-inhibition balance and offer a broader therapeutic spectrum, including salts effective for treating various types of seizures.

Benefits of technology

The novel pyrimidine compounds effectively treat a wide range of seizures with minimal side effects, providing stability and tolerability, and are effective against multidrug-resistant seizures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160219000001
    Figure 2024160219000001
  • Figure 2024160219000002
    Figure 2024160219000002
  • Figure 2024160219000003
    Figure 2024160219000003
Patent Text Reader

Abstract

To provide medicinal uses for a novel compound or a salt thereof useful for treating, preventing and / or diagnosing seizure and the like, in disease involving epileptic seizure or convulsive seizure, and a medicament having a wide treatment spectrum in comparison with existing antiepileptic drugs, whereby the balance of excitation / inhibition can be maintained even at doses that completely suppress epileptic seizure.SOLUTION: There is provided a novel pyrimidine compound represented by the following formula I, where a ring B is pyrimidine, pyridazine, pyridine, pyrazole, benzene or naphthalene. Specifically, for example, the following compound is illustrated.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a heterocyclic compound and a salt thereof. The present invention also relates to a pharmaceutical agent containing a heterocyclic compound or a salt thereof as an active ingredient, which is useful for treating, preventing and / or diagnosing seizures and the like in diseases accompanied by epileptic seizures or convulsive seizures. [Background technology]

[0002] Epilepsy is a common neurological disease with a prevalence of about 1% of the population, with about 1 million patients in Japan. The lifetime incidence rate is said to be 3-4%, and it is estimated that tens of thousands of people develop epilepsy annually. Approximately 70% of these patients are able to suppress seizures by taking existing antiepileptic drugs and can live their daily lives without problems, but the remaining 30% of epilepsy patients are unable to fully control their seizures and are anxious about seizures that may occur at any time. Many of the existing antiepileptic drugs aim to correct the imbalance between excitation and inhibition of neurons by suppressing hyperexcitation and hypersynchronization of neurons, but doses above the optimal dose can disrupt the balance and induce movement disorders and epileptic seizures.

[0003] Patent Document 1 discloses a compound containing a pyrimidine in its structure as a compound to be used for the treatment of diseases or disorders, including epilepsy, which require a modulator of Kv3.1 and / or Kv3.2 channels. Patent Documents 2 and 3 disclose compounds containing a pyrimidine skeleton as kynurenine-3-monooxygenase inhibitors for treating neurodegenerative conditions including epilepsy. Patent Document 4 discloses compounds containing phenoxypyrimidine or pyridyloxypyrimidine in their structures as antagonists and / or inverse agonists of cannabinoid-1 receptors, including for epilepsy. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2011 / 069951 [Patent Document 2] International Publication No. 2013 / 016488 [Patent Document 3] International Publication No. 2011 / 091153 [Patent Document 4] International Publication No. 2004 / 029204 Summary of the Invention [Problem to be solved by the invention]

[0005] One object of the present invention is to provide a medical use of a novel compound and a salt thereof which is effective for the treatment, prevention and / or diagnosis of seizures and the like in diseases accompanied by epileptic seizures or convulsive seizures. Another object of the present invention is to provide a medicine which maintains the balance between excitation and inhibition even at doses which completely suppress epileptic seizures and has a broader therapeutic spectrum than existing antiepileptic drugs.

[0006] As a result of intensive research aimed at solving the above problems, the present inventors have succeeded in synthesizing a novel pyrimidine compound having a broader therapeutic spectrum than existing antiepileptic drugs. The present invention has been completed based on such findings.

[0007] That is, the present invention includes the following aspects. [1] Formula I: TIFF2024160219000001.tif2685[in the formula, D is TIFF2024160219000002.tif2322 or C optionally substituted with halogen 1-6 is alkyl; Ring A is benzene, pyridine, indole or indazole; Ring B is pyrimidine, pyridazine, pyridine, pyrazole, benzene or naphthalene, wherein (i) When ring B is pyrimidine, ring C is selected from the following unsaturated rings and their oxides, dioxides (excluding pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione) and rings in which some or all of the unsaturated bonds in the ring have been reduced with hydrogen; (a) a 3- to 8-membered monocyclic unsaturated heterocycle containing only 1 to 4 nitrogen atoms as ring-constituting heteroatoms; (b) a 7- to 15-membered bicyclic or tricyclic unsaturated heterocycle containing only 1 to 5 nitrogen atoms as ring-constituting heteroatoms; (c) a 7- to 12-membered bicyclic unsaturated heterocycle containing only 1 to 3 oxygen atoms as ring-constituting heteroatoms; (d) a 3- to 8-membered monocyclic unsaturated heterocycle containing one or two oxygen atoms and one to three nitrogen atoms as ring-constituting heteroatoms; (e) a 7- to 12-membered bicyclic unsaturated heterocycle containing 1 or 2 sulfur atoms and 1 to 3 nitrogen atoms as ring-constituting heteroatoms; and (f) 3- to 8-membered monocyclic unsaturated hydrocarbon ring; (ii) when ring B is pyridazine, pyridine, pyrazole, benzene or naphthalene, ring C is pyrimidine-2,4-dione or dihydropyrimidine-2,4-dione; R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl, -CN or -SF5; R 2 is a halogen, C 1-6 Alkyl, -OC 1-6 is alkyl; R 3 is halogen, halogen or -OC 1-6 C optionally substituted with alkyl 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -C 1-6 alkyl -OH, -OH, -CN, -CONH2 or -NH2; L is a bond, C1-6 alkylene, -O- or -S-; k is 0, 1, or 2, and when k is 2, R 1 each independently represents the same or different substituent; m is 0, 1 or 2, and when m is 2, R 2 each independently represents the same or different substituent; n is 0, 1 or 2, and when n is 2, R 3 each independently represents the same or different substituent; A compound represented by the formula: [2] In formula I, D is TIFF2024160219000003.tif2322; Ring A is benzene or pyridine; Ring B is a pyrimidine; Ring C is selected from the following unsaturated rings, their oxides and dioxides (excluding pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione), and rings in which some or all of the unsaturated bonds in the ring have been reduced with hydrogen; Pyridine, Pyridazine, Pyrimidine, Indore, Pyrrolopyridine, Indazole, Benzimidazole, Pyrazolopyridines, Imidazopyridine, Imidazopyrazines, imidazopyridazine, Triazolopyridines, Pyrazolopyrimidines, Imidazopyrimidines, Triazolopyrimidines, Quinoline, Isoquinoline, Naphthyridine, Quinazoline, Quinoxaline, Benzodioxole, Oxazine, oxazepine, benzothiazole, benzene; R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl or -CN; R 2 -OC 1-6 is alkyl; R 3 is halogen, halogen or -OC 1-6 C optionally substituted with alkyl 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -C 1-6 alkyl -OH, -OH, -CN, -CONH2 or -NH2; L is -O-; k is 0, 1, or 2, and when k is 2, R 1 each independently represents the same or different substituent; m is 0 or 1; n is 0, 1 or 2, and when n is 2, R 3 each independently represents the same or different substituent, [3] In formula I, ring C is selected from the following unsaturated rings, their oxides, and rings in which some or all of the unsaturated bonds in the rings have been reduced with hydrogen; Pyridine, Pyridazine, Pyrrolopyridine, Indazole, Pyrazolopyridines, Imidazopyridine, Imidazopyrazines, imidazopyridazine, Pyrazolopyrimidines, Triazolopyrimidines, Quinoline, Isoquinoline, Naphthyridine, Quinoxaline, benzene; R 1is halogen or C optionally substituted with halogen 1-6 is alkyl; R 3 C may be substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl, -OH, -CONH2 or -NH2; L is -O-; k and n are 0 or 1; [2] The compound or salt thereof according to [2], wherein m is 0. [4] In formula I, ring C is selected from the following unsaturated rings, their oxides, and rings in which some or all of the unsaturated bonds in the rings have been reduced with hydrogen; Pyridine, Pyridazine, Pyrazolopyridines, Imidazopyridine; R 3 is -OH or -NH2; L is -O-; k and m are 0; The compound or salt thereof according to [3], wherein n is 0 or 1. [5] In formula I, D is TIFF2024160219000004.tif2322 or C optionally substituted with halogen 1-6 is alkyl; Ring A is benzene or pyridine; Ring B is pyridazine, pyridine, pyrazole, benzene or naphthalene; Ring C is pyrimidine-2,4-dione or dihydropyrimidine-2,4-dione; R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl, -CN or -SF5; R 2 is a halogen, C 1-6 Alkyl, -OC 1-6 is alkyl; R3 is C 1-6 is alkyl; L is a bond, C 1-6 alkylene, -O- or -S-; k is 0, 1, or 2, and when k is 2, R 1 each independently represents the same or different substituent; m is 0, 1 or 2, and when m is 2, R 2 each independently represents the same or different substituent; n is 0, 1 or 2, and when n is 2, R 3 each independently represents the same or different substituent, [6] In formula I, ring A is benzene; Ring B is benzene, pyridine, or pyridazine; Ring C is dihydropyrimidine-2,4-dione; R 1 is a halogen; L is -O-; k is 0 or 1; [5] The compound or salt thereof according to [5], wherein m and n are 0. [7] A compound or a salt thereof selected from the group consisting of the following compounds: TIFF2024160219000005.tif140151 TIFF2024160219000006.tif135147 TIFF2024160219000007.tif154148[8] A compound or a salt thereof according to [7], selected from the group consisting of the following compounds: TIFF2024160219000008.tif113145[9] A pharmaceutical composition comprising a compound or a salt thereof according to any one of [1] to [8] as an active ingredient, and a pharma- ceutically acceptable carrier or excipient.

[10] A therapeutic, preventive and / or diagnostic agent for seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising the compound according to any one of [1] to [8] or a salt thereof.

[11] Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures that progress to bilateral tonic-clonic seizures (secondary generalization of partial seizures), and motor seizures in generalized seizures (tonic-clonic, clonic, The therapeutic, preventive and / or diagnostic agent according to

[10] , which is selected from tonic seizures, myoclonic seizures, myoclonic tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasm seizures) and nonmotor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures of unknown onset (including tonic-clonic seizures and epileptic spasm seizures) and nonmotor seizures (including behavioral arrest seizures).

[12] Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, and unilateral convulsions / hemiplegia. The therapeutic, preventive and / or diagnostic agent according to

[10] , which is selected from epilepsy syndromes, mesial temporal lobe epilepsy syndromes, epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disorders, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), as well as congenital malformations, congenital metabolic disorders (e.g., phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.), and congenital genetic disorders (Rett syndrome, Angelman syndrome, 5p syndrome, 4p syndrome, Down syndrome, etc.).

[13] A pharmaceutical composition for treating, preventing and / or diagnosing seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising a compound according to any one of [1] to [8] or a salt thereof as an active ingredient.

[14] Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and sensory seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), and motor seizures in generalized seizures (tonic-clonic seizures). The composition described in

[13] is selected from motor seizures (including tonic-clonic seizures, tonic seizures, myoclonic seizures, myoclonic tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and non-motor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures in seizures of unknown onset (including tonic-clonic seizures and epileptic spasms) and non-motor seizures (including behavioral arrest seizures).

[15] Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, and unilateral convulsions. the composition according to

[13] , which is selected from epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disease, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), as well as congenital malformations, congenital metabolic disorders (e.g., phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.), and congenital genetic disorders (Rett syndrome, Angelman syndrome, 5p syndrome, 4p syndrome, Down syndrome, etc.).

[16] A method for treating, preventing and / or diagnosing seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising administering to a human an effective amount of a compound according to any one of [1] to [8] or a salt thereof.

[17] Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), and motor seizures in generalized seizures (tonic-clonic seizures). The method according to claim 16, wherein the motor seizures are selected from motor seizures (including tonic-clonic seizures and epileptic spasms) and non-motor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures in seizures of unknown onset (including tonic-clonic seizures and epileptic spasms) and non-motor seizures (including behavioral arrest seizures).

[18] Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, and unilateral convulsive seizures. 16] The method according to claim 15, wherein the epilepsy is selected from the group consisting of epilepsy due to convulsion / hemiplegia / epilepsy syndrome, mesial temporal lobe epilepsy syndrome, epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disease, epilepsy associated with brain tumor, epilepsy associated with neurodegenerative disease, epilepsy associated with autoimmune disease, etc.), congenital malformation, congenital metabolic disorder (e.g., phenylketonuria, mitochondrial disease, lysosomal disease, Sturge-Weber syndrome, etc.), and congenital genetic abnormality (Rett syndrome, Angelman syndrome, 5p syndrome, 4p syndrome, Down syndrome, etc.).

[19] The compound or salt thereof according to any one of [1] to [8] for use in the treatment, prevention and / or diagnosis of seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus).

[20] Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), and motor seizures in generalized seizures (tonic-clonic, clonic-clonic, and tonic-clonic). The compound or salt thereof according to

[19] , which is selected from motor seizures (including tonic seizures, myoclonic seizures, myoclonic tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and nonmotor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures in seizures of unknown onset (including tonic-clonic seizures and epileptic spasms) and nonmotor seizures (including behavioral arrest seizures).

[21] Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, and unilateral convulsions. The compound or salt thereof according to

[19] , which is selected from hemiplegia epilepsy syndrome, mesial temporal lobe epilepsy syndrome, epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disease, epilepsy associated with brain tumor, epilepsy associated with neurodegenerative disease, epilepsy associated with autoimmune disease, etc.), as well as congenital malformation, congenital metabolic disorder (e.g., phenylketonuria, mitochondrial disease, lysosomal disease, Sturge-Weber syndrome, etc.), and congenital genetic abnormality (Rett syndrome, Angelman syndrome, 5p syndrome, 4p syndrome, Down syndrome, etc.).

[22] Use of the compound or a salt thereof according to any one of [1] to [8] in the manufacture of a medicament for treating, preventing and / or diagnosing seizures in diseases accompanied by epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus).

[23] Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and sensory seizures), focal seizures that progress to bilateral tonic-clonic seizures (secondary generalization of partial seizures), and motor seizures in generalized seizures (tonic-clonic seizures). The use described in

[22] is selected from motor seizures (including tonic-clonic seizures, tonic seizures, myoclonic seizures, myoclonic tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and non-motor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures in seizures of unknown onset (including tonic-clonic seizures and epileptic spasms) and non-motor seizures (including behavioral arrest seizures).

[24] Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, unilateral spasms,

[22] The use according to the above-mentioned item, which is selected from convulsion / hemiplegia / epilepsy syndrome, mesial temporal lobe epilepsy syndrome, epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disorders, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), as well as congenital malformations, congenital metabolic disorders (e.g. phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.) and congenital genetic disorders (Rett syndrome, Angelman syndrome, 5p-syndrome, 4p-syndrome, Down syndrome, etc.).

[0008] The compound of the present invention and its salts have excellent effects in the treatment, prevention and / or diagnosis of diseases accompanied by epileptic seizures or convulsive seizures. In addition, the compound of the present invention and its salts have excellent characteristics for use as an active ingredient of pharmaceuticals, such as fewer side effects and excellent characteristics in terms of tolerability and stability (storage stability, metabolic stability, etc.). Furthermore, the compound of the present invention and its salts have a broader therapeutic spectrum than existing antiepileptic drugs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The words and terms used in this specification are explained in detail below. "C 1-6 Alkyl" is C 1-6 Specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, and the like. In addition, C in which 1 to 3 hydrogen atoms are replaced by deuterium atoms 1-6 Alkyl is also included.

[0010] "Halogen" is fluorine, chlorine, bromine or iodine. Preferably, it is fluorine, chlorine or bromine, more preferably fluorine or chlorine.

[0011] "C which may be substituted with halogen 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms (C 1-6) is a straight-chain or branched alkyl group, specific examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, 3-methylpentyl, fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, 2-fluoroethyl, 2-chloroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 1,1,2,2-tetrafluoroethyl, 3-chloropropyl, 2,3-dichloropropyl, 4,4,4-trichlorobutyl, 4-fluorobutyl, 5-chloropentyl, 3-chloro-2-methylpropyl, 5-bromohexyl, 5,6-dibromohexyl, and the like.

[0012] "C 1-6 Alkylene is a group that has 1 to 6 carbon atoms (C 1-6 ) is a straight-chain or branched alkylene group, specific examples of which include methylene, ethylene, 1-methylethylene, 2-methylethylene, trimethylene, 2-methyltrimethylene, 2,2-dimethyltrimethylene, 1-methyltrimethylene, methylmethylene, ethylmethylene, dimethylmethylene, tetramethylene, pentamethylene, hexamethylene, and the like. Also, "C 1-6 "Alkylene" is a C alkylene in which one to three hydrogen atoms are replaced by deuterium atoms. 1-6 Alkylene is also included.

[0013] Each group defined in the present specification may be bonded to another group via a linker such as, for example, -O-, -CO-, -COO-, -S-, -SO-, -SO2-, -Si-, -O-CO-, etc.

[0014] Various substituents in the compound of the present invention represented by the general formula [I] (hereinafter referred to as "compound [I] of the present invention") are described below.

[0015] D in the compound [I] of the present invention is (R 1 )k Ring A optionally substituted with or C optionally substituted with halogen 1-6 It is an alkyl.

[0016] Ring A in the compound [I] of the present invention is benzene, pyridine, indole or indazole, and is preferably benzene or pyridine.

[0017] In the compound [I] of the present invention, when the ring B is pyrimidine, the ring C is selected from the following unsaturated rings, their oxides and dioxides (excluding pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione), and rings in which a part or all of the unsaturated bonds in the ring are reduced with hydrogen: (a) a 3- to 8-membered monocyclic unsaturated heterocycle containing only 1 to 4 nitrogen atoms as ring-constituting heteroatoms; (b) a 7- to 15-membered bicyclic or tricyclic unsaturated heterocycle containing only 1 to 5 nitrogen atoms as ring-constituting heteroatoms; (c) a 7- to 12-membered bicyclic unsaturated heterocycle containing only 1 to 3 oxygen atoms as ring-constituting heteroatoms; (d) a 3- to 8-membered monocyclic unsaturated heterocycle containing one or two oxygen atoms and one to three nitrogen atoms as ring-constituting heteroatoms; (e) a 7- to 12-membered bicyclic unsaturated heterocycle containing 1 or 2 sulfur atoms and 1 to 3 nitrogen atoms as ring-constituting heteroatoms; (f) 3- to 8-membered monocyclic unsaturated hydrocarbon ring.

[0018] Specific examples of the above (a) 3- to 8-membered monocyclic unsaturated heterocycles containing only 1 to 4 nitrogen atoms as ring-constituting heteroatoms, as well as their oxides and dioxides (excluding pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione), and rings in which part or all of the unsaturated bonds in the ring have been reduced with hydrogen include: Pyridine, piperidine, pyridine-1-oxide, pyridin-2(1H)-one, pyrimidine, tetrahydropyrimidine, tetrahydropyrimidin-2(1H)-one, pyridazine, pyridazin-3(2H)-one, 4,5-dihydropyridazine, 4,5-dihydropyridazin-3(2H)-one etc. can be mentioned.

[0019] Specific examples of the 7- to 15-membered bicyclic or tricyclic unsaturated heterocycle containing only 1 to 5 nitrogen atoms as the ring-constituting heteroatoms of (b) above, as well as their oxides, dioxides, and rings in which part or all of the unsaturated bonds in the ring have been reduced with hydrogen, include: Indole, indoline, indolin-2-one, indolin-3-one, indoline-2,3-dione, benzimidazole (e.g., 1H-benzo[d]imidazole), dihydrobenzimidazole (e.g., 2,3-dihydro-1H-benzo[d]imidazole), indazole, dihydroindazole (e.g., 2,3-dihydro-1H-indazole), quinoline, quinolin-2(1H)-one, dihydroquinoline (e.g., 1,2-dihydroquinoline, 3,4-dihydroquinoline), 3 ,4-Dihydroquinolin-2(1H)-one, tetrahydroquinoline (e.g., 1,2,3,4-tetrahydroquinoline), isoquinoline, isoquinolin-1(2H)-one, 1,3-dihydroisoquinoline, 3,4-dihydroisoquinoline, 3,4-dihydroisoquinolin-1(2H)-one, triazolopyrimidines (e.g., [1,2,4]triazolo[1,5-a]pyrimidine), triazolopyridines (e.g., [1,2,3]triazolo[1,5-a]pyridine, [1,2,4]triazolo[ [1,5-a]pyridine, [1,2,4]triazolo[4,3-a]pyridine, imidazopyridine (e.g., imidazo[1,5-a]pyridine), imidazopyrazine (e.g., imidazo[1,2-a]pyrazine), imidazopyrimidine (e.g., imidazo[1,2-a]pyrimidine), imidazopyridazine (e.g., imidazo[1,2-b]pyridazine), naphthyridine (e.g., 1,5-naphthyridine, 1,8-naphthyridine), quinoxaline, dihydroquinoxaline (e.g., 1,2-dihydroquinoxaline, quinoxaline), tetrahydroquinoxaline (e.g., 1,2,3,4-tetrahydroquinoxaline), quinazoline, quinazolin-4(3H)-one, dihydroquinazoline (e.g., 2,3-dihydroquinazoline), pyrazolopyridines (e.g., pyrazolo[1,5-a]pyridine, pyrazolo[3,4-b]pyridine), pyrrolopyridines (e.g., pyrrolo[2,3-b]pyridine), pyrrolo[2,3-b]pyridin-2(3H)-one, pyrazolopyrimidine (e.g., pyrazolo[1,5-a]pyrimidine) etc. can be mentioned.

[0020] Specific examples of the 7- to 12-membered bicyclic unsaturated heterocycle containing only 1 to 3 oxygen atoms as the ring-constituting heteroatoms of (c) above, as well as their oxides, dioxides, and rings in which part or all of the unsaturated bonds in the ring have been reduced with hydrogen, include: Benzodioxoles (e.g., benzo[d][1,3]dioxole, benzo[c][1,2]dioxole) etc. can be mentioned.

[0021] Specific examples of the 3- to 8-membered monocyclic unsaturated heterocycle containing one or two oxygen atoms and one to three nitrogen atoms as ring-constituting heteroatoms of the above (d), as well as their oxides, dioxides, and rings in which part or all of the unsaturated bonds in the ring have been reduced with hydrogen include: Oxazepines (e.g., 1,2-oxazepine, 1,3-oxazepine, 1,4-oxazepine), dihydrooxazepines, tetrahydrooxazepines, oxazepanes (e.g., 1,2-oxazepane, 1,3-oxazepane, 1,4-oxazepane), 1,4-oxazepan-2-ones, oxazines (e.g., 1,4-oxazine), dihydrooxazines (3,4-dihydro 2H-1,4-oxazepines), morpholines, morpholin-3-ones etc. can be mentioned.

[0022] Specific examples of the 7- to 12-membered bicyclic unsaturated heterocycle containing one or two sulfur atoms and one to three nitrogen atoms as ring-constituting heteroatoms of the above (e), as well as their oxides, dioxides, and rings in which part or all of the unsaturated bonds in the ring have been reduced with hydrogen, include: Benzothiazoles (e.g., benzo[d]thiazole) etc. can be mentioned.

[0023] Specific examples of the 3- to 8-membered monocyclic unsaturated hydrocarbon ring of the above (f), as well as their oxides, dioxides, and rings in which part or all of the unsaturated bonds in these rings have been reduced with hydrogen include: Benzene, cyclohexene, cyclohexane etc. can be mentioned.

[0024] Preferably, when ring B is pyrimidine, ring C is selected from the following unsaturated rings and their oxides, dioxides (except for pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione) and rings in which some or all of the unsaturated bonds in the ring have been reduced with hydrogen: Pyridine, Pyridazine, Pyrimidine, Indore, Pyrrolopyridine, Indazole, Benzimidazole, Pyrazolopyridines, Imidazopyridine, Imidazopyrazines, imidazopyridazine, Triazolopyridines, Pyrazolopyrimidines, Imidazopyrimidines, Triazolopyrimidines, Quinoline, Isoquinoline, Naphthyridine, Quinazoline, Quinoxaline, Benzodioxole, Oxazine, oxazepine, benzothiazole, benzene.

[0025] In the compound [I] of the present invention, when ring B is benzene, naphthalene, pyridine, pyrazole or pyridazine, ring C is pyrimidine-2,4-dione or dihydropyrimidine-2,4-dione. Preferably, ring B is benzene or pyridine.

[0026] R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -CN or -SF5. Preferably halogen, C optionally substituted with halogen1-6 -OC optionally substituted with alkyl or halogen 1-6 It is alkyl, and more preferably fluorine, methyl, trifluoromethyl or -O-trifluoromethyl.

[0027] R 2 is a halogen, C 1-6 Alkyl or -OC 1-6 It is alkyl, preferably fluorine, methyl or -O-methyl.

[0028] R 3 is halogen, halogen or C 1-6 C optionally substituted with alkyl-O- 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -C 1-6 Alkyl-OH, -OH, -CN, -CONH2 or -NH2. Preferably, C optionally substituted with halogen 1-6 Alkyl, -OC 1-6 It is preferably alkyl, -OH, -CONH2 or -NH2, and more preferably methyl, trifluoromethyl, -O-methyl, -OH, -CONH2 or -NH2.

[0029] L is a bond, C 1-6 It is alkylene, -O- or -S-, preferably a bond or -O-, and more preferably -O-.

[0030] k is 0, 1, or 2, and when k is 2, R 1 each independently represents the same or different substituent, preferably 0 or 1, and more preferably 0.

[0031] m is 0, 1 or 2, and when m is 2, R 2 each independently represents the same or different substituent, preferably 0 or 1, and more preferably 0.

[0032] n is 0, 1 or 2, and when n is 2, R 3each independently represents the same or different substituent, preferably 0 or 1.

[0033] In the compound [I] of the present invention, the above-mentioned options and preferred embodiments regarding the substituents include all combinations thereof, so long as these are not contradictory combinations.

[0034] Preferred embodiments of the compound [I] of the present invention are shown below. (1-1) In formula I, D is TIFF2024160219000009.tif2322; Ring A is benzene or pyridine; Ring B is a pyrimidine; Ring C is selected from the following unsaturated rings, their oxides and dioxides (excluding pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione), and rings in which some or all of the unsaturated bonds in the ring have been reduced with hydrogen; Pyridine, Pyridazine, Pyrimidine, Indore, Pyrrolopyridine, Indazole, Benzimidazole, Pyrazolopyridines, Imidazopyridine, Imidazopyrazines, imidazopyridazine, Triazolopyridines, Pyrazolopyrimidines, Imidazopyrimidines, Triazolopyrimidines, Quinoline, Isoquinoline, Naphthyridine, Quinazoline, Quinoxaline, Benzodioxole, Oxazine, oxazepine, benzothiazole, benzene; R1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl or -CN; R 2 -OC 1-6 is alkyl; R 3 is halogen, halogen or -OC 1-6 C optionally substituted with alkyl 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -C 1-6 alkyl -OH, -OH, -CN, -CONH2 or -NH2; L is -O-; k is 0, 1, or 2, and when k is 2, R 1 each independently represents the same or different substituent; m is 0 or 1; n is 0, 1 or 2, and when n is 2, R 3 each independently represents the same or different substituent. (1-2) In formula I, ring C is selected from the following unsaturated rings, their oxides, and rings in which some or all of the unsaturated bonds in the rings have been reduced with hydrogen; Pyridine, Pyridazine, Pyrrolopyridine, Indazole, Pyrazolopyridines, Imidazopyridine, Imidazopyrazines, imidazopyridazine, Pyrazolopyrimidines, Triazolopyrimidines, Quinoline, Isoquinoline, Naphthyridine, Quinoxaline, benzene; R 1 is halogen or C optionally substituted with halogen 1-6 is alkyl; R3 C may be substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl, -OH, -CONH2 or -NH2; L is -O-; k and n are 0 or 1; m is 0. (1-3) In formula I, ring C is selected from the following unsaturated rings, their oxides, and rings in which some or all of the unsaturated bonds in the rings have been reduced with hydrogen; Pyridine, Pyridazine, Pyrazolopyridines, Imidazopyridine; R 3 is -OH or -NH2; L is -O-; k and m are 0; n is 0 or 1. (1-4) A compound selected from the group consisting of the following compounds or a salt thereof: TIFF2024160219000010.tif140148 TIFF2024160219000011.tif140153 TIFF2024160219000012.tif84146(1-5) A compound or a salt thereof selected from the group consisting of the following compounds: TIFF2024160219000013.tif100151

[0035] Another preferred embodiment of the compound [I] of the present invention is shown below. (2-1) In formula I, D is TIFF2024160219000014.tif2322 or C optionally substituted with halogen 1-6 is alkyl; Ring A is benzene or pyridine; Ring B is pyridazine, pyridine, pyrazole, benzene or naphthalene; Ring C is pyrimidine-2,4-dione or dihydropyrimidine-2,4-dione; R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl, -CN or -SF5; R 2 is a halogen, C 1-6 Alkyl, -OC 1-6 is alkyl; R 3 is C 1-6 is alkyl; L is a bond, C 1-6 alkylene, -O- or -S-; k is 0, 1, or 2, and when k is 2, R 1 each independently represents the same or different substituent; m is 0, 1 or 2, and when m is 2, R 2 each independently represents the same or different substituent; n is 0, 1 or 2, and when n is 2, R 3 each independently represents the same or different substituent. (2-2) In formula I, ring A is benzene; Ring B is benzene, pyridine, or pyridazine; Ring C is dihydropyrimidine-2,4-dione; R 1 is a halogen; L is -O-; k is 0 or 1; m and n are 0. (2-3) A compound selected from the group consisting of the following compounds or a salt thereof: TIFF2024160219000015.tif50106(2-4) The following compounds or salts thereof. TIFF2024160219000016.tif3263

[0036] In this specification, the presentation of preferred aspects and options for different features of the compounds, methods, and compositions of the present invention also includes the presentation of combinations of preferred aspects and options for the different features, so long as they are combinable and not inconsistent.

[0037] The method for producing the compound [I] of the present invention will be described below. The compound [I] of the present invention can be produced, for example, based on the production method shown below. The production methods shown below are merely examples, and the production method of the compound [I] is not limited to these.

[0038] In the following reaction formulas, when an alkylation reaction, amination reaction, esterification reaction, amidation reaction, etherification reaction, nucleophilic substitution reaction, addition reaction, oxidation reaction, reduction reaction, etc. are carried out, these reactions are carried out according to a method known per se. Examples of such methods include those described in Experimental Chemistry Lectures (5th Edition, edited by the Chemical Society of Japan, Maruzen Co., Ltd.), Organic Functional Group Preparations 2nd Edition, published by ACADEMIC PRESS, INC. in 1989, Comprehensive Organic Transformations, published by VCH Publishers Inc. in 1989, and "Greene's Protective Groups in Organic Synthesis" (4th Edition, 2006) by PGM Wuts and T.W. Greene, and the like.

[0039] Reaction Scheme 1-1 TIFF2024160219000017.tif32167 (wherein Y and Y′ are leaving groups, and the other symbols are as defined above.)

[0040] The compound [I] of the present invention can be produced by the reaction shown in the above reaction formula 1-1. Specifically, the compound [IIa] is added with a cyclic pinacol ester of boronic acid ((BPin)2) to give the compound [IIa'], and the compound [IIIa] is bonded to the compound [IIa'] by Suzuki cross coupling to produce the compound [I].

[0041] The "leaving group" used in the above reaction is specifically halogen, C 1-18 Alkanesulfonyl, C 1-8 Alkanesulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, trihalomethanesulfonyloxy, sulfonio, toluenesulfoxy, etc. A preferred leaving group in this reaction is halogen.

[0042] The above "halogen" is fluorine, chlorine, bromine or iodine.

[0043] The above "C 1-18 Examples of "alkanesulfonyl" include C 1-18 Straight-chain or branched-chain alkanesulfonyl is included, and specific examples thereof include methanesulfonyl, 1-propanesulfonyl, 2-propanesulfonyl, butanesulfonyl, cyclohexanesulfonyl, dodecanesulfonyl, octadecanesulfonyl, and the like.

[0044] Examples of the above "lower alkanesulfonyloxy" include C 1-6 Specific examples thereof include straight-chain or branched-chain alkanesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, 1-propanesulfonyloxy, 2-propanesulfonyloxy, 1-butanesulfonyloxy, 3-butanesulfonyloxy, 1-pentanesulfonyloxy, and 1-hexanesulfonyloxy.

[0045] Examples of the above "arenesulfonyloxy" include halogen, nitro, C 1-6 Linear or branched alkoxy groups and C 1-6It includes benzenesulfonyloxy, naphthalenesulfonyloxy, etc., which may have 1 to 3 substituents selected from the group consisting of straight-chain or branched-chain alkyl groups on the phenyl ring. Specific examples of these "benzenesulfonyloxy which may have a substituent" include benzenesulfonyloxy, 4-methylbenzenesulfonyloxy, 2-methylbenzenesulfonyloxy, 4-nitrobenzenesulfonyloxy, 4-methoxybenzenesulfonyloxy, 2-nitrobenzenesulfonyloxy, 3-chlorobenzenesulfonyloxy, etc. Specific examples of the above "naphthalenesulfonyloxy" include α-naphthylsulfonyloxy, β-naphthylsulfonyloxy, etc.

[0046] Examples of the above "aralkanesulfonyloxy" include halogen, nitro, C 1-6 Linear or branched alkoxy groups and C 1-6 C substituted with phenyl, which may have 1 to 3 substituents on the phenyl ring selected from the group consisting of straight-chain or branched-chain alkyl groups 1-6 Linear or branched alkanesulfonyloxy, naphthyl-substituted C 1-6 It includes straight-chain or branched-chain alkanesulfonyloxy. Specific examples of these "alkanesulfonyloxy substituted with phenyl" include phenylmethanesulfonyloxy, 2-phenylethanesulfonyloxy, 4-phenylbutanesulfonyloxy, 4-tolylmethanesulfonyloxy, 2-tolylmethanesulfonyloxy, (4-nitrophenyl)methanesulfonyloxy, (4-methoxyphenyl)methanesulfonyloxy, (3-chlorophenyl)methanesulfonyloxy, etc. Examples of the above "alkanesulfonyloxy substituted with naphthyl" include α-naphthylmethanesulfonyloxy, β-naphthylmethanesulfonyloxy, etc.

[0047] A specific example of the above "trihaloalkanesulfonyloxy" is trifluoromethanesulfonyloxy.

[0048] Specific examples of the above "sulfonio" include dimethylsulfonio, diethylsulfonio, dipropylsulfonio, di(2-cyanoethyl)sulfonio, di(2-nitroethyl)sulfonio, di-(aminoethyl)sulfonio, di(2-methylaminoethyl)sulfonio, di-(2-dimethylaminoethyl)sulfonio, di-(2-hydroxyethyl)sulfonio, di-(3-hydroxypropyl)sulfonio, di-(2-methoxyethyl)sulfonio, di-(2-carbamoylethyl)sulfonio, di-(2-carbamoylethyl)sulfonio, di-(2-carboxyethyl)sulfonio, di-(2-methoxycarbonylethyl)sulfonio, diphenylsulfonio, and the like.

[0049] The "palladium compound" used in this reaction is not particularly limited, but examples thereof include tetravalent palladium catalysts such as sodium hexachloropalladate(IV) tetrahydrate and potassium hexachloropalladate(IV); [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (PdCl2(dppf)DCM), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (XPhos Pd G3), palladium (II) chloride, palladium (II) bromide, palladium (II) acetate (PD(OAc)2), palladium acetylacetonate (II), dichlorobis(benzonitrile)palladium (II), dichlorobis(acetonitrile)palladium (II), dichlorobis(triphenylphosphine)palladium (II), dichlorotetraamminepalladium (II), dichloro(cycloocta-1,5-diene)palladium (II), palladium (II) trifluoroacetate, and other divalent palladium catalysts; tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3), tris(dibenzylideneacetone)dipalladium (0) chloroform complex, tetrakis(triphenylphosphine)palladium (0) (Pd(PPh3)4), and other zero-valent palladium catalysts. These palladium compounds are used alone or in combination of two or more.

[0050] In this reaction, the amount of the palladium compound used is not particularly limited, but is usually in the range of 0.000001 to 20 moles in terms of palladium per mole of compound [IIa]. More preferably, the amount of the palladium compound used is in the range of 0.0001 to 5 moles in terms of palladium per mole of compound [IIa].

[0051] The "base" used in this reaction includes, for example, inorganic bases, organic bases, etc. Examples of the "inorganic base" include alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide), alkaline earth metal hydroxides (e.g., magnesium hydroxide, calcium hydroxide), alkali metal carbonates (e.g., sodium carbonate, potassium carbonate), alkaline earth metal carbonates (e.g., magnesium carbonate, calcium carbonate), alkali metal hydrogen carbonates (e.g., sodium hydrogen carbonate, potassium hydrogen carbonate), alkali metal phosphates (e.g., sodium phosphate, potassium phosphate), alkaline earth metal phosphates (e.g., sodium phosphate, potassium phosphate), etc. Examples of the "organic base" include trialkylamines (e.g., trimethylamine, triethylamine, and diisopropylethylamine), dialkylamines (e.g., diethylamine, diisopropylamine), picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), etc. These bases may be used alone or in combination of two or more.

[0052] The "boronic acid" or "boronic acid ester" used in this reaction may be separately produced, isolated and purified, or, for example, a precursor halogenated compound or the like may be reacted with bis-pinacoldiborane in the presence of a palladium compound and used in Suzuki cross-coupling without isolation and purification.

[0053] The "solvent" used in this reaction may be any solvent inert to the reaction, such as water, ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether), hydrocarbons (e.g., hexane), halohydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, carbon tetrachloride), aromatic hydrocarbons (e.g., benzene, toluene, xylene), lower alcohols (e.g., methanol, ethanol, isopropanol), polar solvents (e.g., N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile), ketones (e.g., acetone, methyl ethyl ketone), esters (e.g., methyl acetate, ethyl acetate). These solvents may be used alone or in combination of two or more.

[0054] Other reaction conditions (such as reaction temperature and reaction time) can be appropriately determined based on known Suzuki cross-coupling reactions.

[0055] Reaction Scheme 1-2 TIFF2024160219000018.tif38127 (wherein Y is a leaving group, and the other symbols are as defined above.)

[0056] The compound [I] of the present invention can be produced by the reaction shown in the above reaction formula 1-2. Specifically, the compound [I] can be produced by coupling the compound [IIa] to the compound [IIIb] by Suzuki cross coupling.

[0057] The palladium compound, base, solvent, etc. that can be used in the above reaction scheme 1-2 are the same as those that can be used in the reaction scheme 1-1.

[0058] Reaction Scheme 1-3 TIFF2024160219000019.tif38121 (wherein Y is a leaving group, and the other symbols are as defined above.)

[0059] The compound [I] of the present invention can be produced by the reaction shown in the above reaction formula 1-3. Specifically, the compound [I] can be produced by coupling the compound [IIa] to the compound [IIIc] by Suzuki cross coupling.

[0060] The palladium compound, base, solvent, etc. that can be used in the above Reaction Scheme 1-3 are the same as those that can be used in Reaction Scheme 1-1.

[0061] Reaction Scheme 2-1 TIFF2024160219000020.tif35119 (wherein each symbol has the same meaning as above.)

[0062] The compound [Ia] included in the compound [I] of the present invention can be produced by the reaction shown in the above reaction formula 2-1. Specifically, the compound [VI] is added to the amino group of the compound [IIb], and then the chlorine of the product is eliminated and cyclized to produce the compound [Ia].

[0063] The "base" used in this reaction includes, for example, inorganic bases, organic bases, etc. Examples of the "inorganic base" include alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide), alkali metal carbonates (e.g., sodium carbonate, potassium carbonate), alkali metal hydrogen carbonates (e.g., sodium hydrogen carbonate, potassium hydrogen carbonate), sodium hydride (NaH), sodium hexamethyldisilazide (NaHMDS), etc. Examples of the "organic base" include trialkylamines (e.g., trimethylamine, triethylamine), Hunig's base (N,N-diisopropylethylamine), pyridine, N-methylmorpholine, etc.

[0064] The "solvent" used in this reaction may be any solvent inert to the reaction, such as water, ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether), hydrocarbons (e.g., hexane), halohydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, carbon tetrachloride), aromatic hydrocarbons (e.g., benzene, toluene, xylene), lower alcohols (e.g., methanol, ethanol, isopropanol), polar solvents (e.g., N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile), ketones (e.g., acetone, methyl ethyl ketone), esters (e.g., methyl acetate, ethyl acetate). These solvents may be used alone or in combination of two or more.

[0065] Other reaction conditions (such as reaction temperature and reaction time) can be appropriately determined based on condensation reactions known per se. For example, the reaction temperature is from room temperature to the reflux temperature of the solvent, and the reaction time is from 10 minutes to 10 hours.

[0066] Reaction Scheme 2-2 TIFF2024160219000021.tif28115 (wherein each symbol has the same meaning as above.)

[0067] Compound [Ib], which is included in compound [I] of the present invention, can be produced by the reaction shown in the above reaction formula 2-2. Specifically, compound [III] (acrylic acid) is added to the amino group of compound [IIb] in 1,4-addition, and then the amino group of the product is converted to a urea derivative using urea, followed by cyclization (intramolecular amidation), to produce compound [Ib].

[0068] The "solvent" used in the above reaction may be any solvent inert to the reaction, and examples thereof include water, ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether), hydrocarbons (e.g., hexane), halohydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, carbon tetrachloride), aromatic hydrocarbons (e.g., benzene, toluene, xylene), lower alcohols (e.g., methanol, ethanol, isopropanol), polar solvents (e.g., N,N-dimethylformamide (DMF), N-methylpyrrolidine (NMP), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile), ketones (e.g., acetone, methyl ethyl ketone), and esters (e.g., methyl acetate, ethyl acetate). These solvents may be used alone or in combination of two or more.

[0069] The "acid" used in the above reaction includes, for example, inorganic acids, organic acids, etc. Examples of the "inorganic acid" include hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid, etc. Examples of the "organic acid" include acetic acid, trifluoroacetic acid, oxalic acid, phthalic acid, fumaric acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid, 10-camphorsulfonic acid, etc.

[0070] Other reaction conditions (such as reaction temperature and reaction time) can be appropriately determined based on the known 1,4-addition reaction and amidation reaction.

[0071] Reaction Scheme 3-1 TIFF2024160219000022.tif33153 (wherein Y is a leaving group and L1 is -O-, -S- or C 1-6 alkylene, and the other symbols are as defined above.)

[0072] The compound [Ic] included in the compound [I] of the present invention can be produced by the reaction shown in the above reaction formula 3-1. Specifically, the compound [Ic] can be produced by eliminating the leaving group Y of the compound [V] and replacing it with the compound [IV].

[0073] The "base" used in this reaction may be, for example, an inorganic base. Examples of the "inorganic base" include alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide), alkali metal carbonates (e.g., sodium carbonate, potassium carbonate), alkali metal hydrogen carbonates (e.g., sodium hydrogen carbonate, potassium hydrogen carbonate), sodium hydride (NaH), sodium hexamethyldisilazide (NaHMDS), etc. Examples of the "organic base" include trialkylamines (e.g., trimethylamine, triethylamine), Hunig's base (N,N-diisopropylethylamine), pyridine, N-methylmorpholine, etc.

[0074] The "solvent" used in this reaction may be any solvent inert to the reaction, such as water, ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether), hydrocarbons (e.g., hexane), halohydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, carbon tetrachloride), aromatic hydrocarbons (e.g., benzene, toluene, xylene), lower alcohols (e.g., methanol, ethanol, isopropanol), polar solvents (e.g., N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile), ketones (e.g., acetone, methyl ethyl ketone), esters (e.g., methyl acetate, ethyl acetate). These solvents may be used alone or in combination of two or more.

[0075] Other reaction conditions (such as reaction temperature and reaction time) can be appropriately determined based on known condensation reactions, and for example, the reaction temperature is from room temperature to 100° C., and the reaction time is from 1 hour to 10 hours.

[0076] In each reaction in the above reaction scheme, the product can be used in the next reaction as the reaction solution or as a crude product, or it can be isolated from the reaction mixture in a conventional manner or easily purified by a conventional separation means, such as recrystallization, distillation, or chromatography.

[0077] The starting compounds, intermediate compounds, and target compounds in each step, as well as the compound [I] of the present invention, include geometric isomers, stereoisomers, optical isomers, and tautomers. Various isomers can be separated by a general optical resolution method. They can also be produced from suitable optically active starting compounds.

[0078] The compound [I] of the present invention can be produced by the synthesis methods shown in the above reaction schemes or methods analogous thereto.

[0079] In the production of the compound [I] of the present invention, the starting compounds may be commercially available compounds, or compounds produced according to a method known per se or a method analogous thereto, unless a specific method is described.

[0080] The starting compounds and the target compounds in each step above can be used in the form of suitable salts. Examples of such salts include the same salts as those exemplified below as salts of compound [I] of the present invention.

[0081] When the compound obtained in each step or the commercially available product is a free compound, it can be converted to the desired salt by a method known per se. When the compound obtained in each step or the commercially available product is a salt, it can be converted to the free form or another type of desired salt by a method known per se.

[0082] Compound [I] of the present invention also includes its pharma- ceutically acceptable salt form, and may form a salt with a base depending on the type of acid addition salt or substituent. Examples of such "acids" include inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and organic acids such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, citric acid, tartaric acid, maleic acid, fumaric acid, malic acid, and lactic acid. Examples of such "bases" include inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and potassium bicarbonate, and organic bases such as methylamine, diethylamine, trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, guanidine, pyridine, picoline, and choline, and ammonium salts. Also, salts may be formed with amino acids such as lysine, arginine, aspartic acid, and glutamic acid.

[0083] The present invention also includes various hydrates, solvates and crystalline polymorphs of compound [I] and its salts.

[0084] The compound [I] of the present invention includes compounds in which one or more atoms are replaced with one or more isotope atoms. Examples of isotope atoms include deuterium ( 2 H), tritium ( 3 H), 13 C. 15 N, 18 Examples include O.

[0085] The compound [I] of the present invention also includes pharma- ceutically acceptable prodrugs. Substituents that can be modified to form prodrugs include reactive functional groups such as -OH, -COOH, and amino. Modification groups for these functional groups may be appropriately selected from the "substituents" in this specification.

[0086] The compound [I] or a salt thereof of the present invention may be a pharma- ceutically acceptable co-crystal or co-crystal salt. Here, the term "co-crystal or co-crystal salt" refers to a crystalline substance consisting of two or more unique solids at room temperature, each of which has different physical properties (e.g., structure, melting point, heat of fusion, etc.). The co-crystal and co-crystal salt can be prepared by applying a known co-crystallization method.

[0087] The compound [I] and its salts of the present invention have excellent effects on the treatment, prevention and / or diagnosis of epileptic seizures or convulsive seizures in diseases accompanied by epileptic seizures, which are applicable to any of the following types of seizures: Motor onset seizures (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures and tonic seizures) and non-motor onset seizures (including autonomic seizures, behavioral arrest seizures, cognitive seizures, affective seizures and sensory seizures) in focal seizures (sometimes called partial seizures), seizures progressing to bilateral tonic-clonic seizures from focal seizures (secondarily generalized partial seizures); motor seizures (including tonic-clonic seizures, clonic seizures, tonic seizures, myoclonic tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and non-motor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures) in seizures of unknown onset and non-motor seizures (including behavioral arrest seizures). Diseases accompanied by epileptic seizures or convulsive seizures include, for example, Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, These include unilateral convulsion / hemiplegia / epilepsy syndrome, mesial temporal lobe epilepsy syndrome, epilepsy attributable to structural or metabolic causes (e.g., post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disease, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), as well as congenital malformations, congenital metabolic disorders (e.g., phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.), and congenital genetic abnormalities (Rett syndrome, Angelman syndrome, 5p-syndrome, 4p-syndrome, Down syndrome, etc.). In addition, the compound [I] and its salts of the present invention are also effective in treating, preventing and / or diagnosing multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus. In the present invention, multidrug-resistant seizures or refractory seizures refer to seizures that cannot be controlled due to ineffectiveness or insufficient effect of one or more antiepileptic drugs, regardless of the above-mentioned epileptic seizure types. Furthermore, the compound [I] of the present invention and its salts have excellent characteristics for use as active ingredients of pharmaceuticals, such as fewer side effects and excellent characteristics in terms of tolerability and stability (storage stability, metabolic stability, etc.) These compounds of the present invention are also effective as prophylactic and / or therapeutic agents for intractable epilepsy attacks for which conventional drug treatments are ineffective.

[0088] Next, a medical preparation (hereinafter also referred to as a "pharmaceutical composition") containing the compound [I] of the present invention or a salt thereof as an active ingredient will be described.

[0089] The above medical preparation is a preparation of the compound [I] of the present invention or a salt thereof in the form of a conventional medical preparation, and is prepared by using the compound [I] of the present invention or a salt thereof and a pharma- ceutically acceptable carrier, such as a commonly used diluent or excipient, such as a filler, extender, binder, wetting agent, disintegrant, surfactant, or lubricant.

[0090] Such medical preparations can be selected from a variety of forms depending on the treatment purpose, and examples include tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injections (liquids, suspensions, etc.), etc.

[0091] A wide variety of known carriers can be used as carriers for forming tablets, including, for example, excipients such as lactose; binders such as polyvinylpyrrolidone; disintegrants such as starch; absorption promoters such as sodium lauryl sulfate; moisturizers such as glycerin and starch; adsorbents such as colloidal silicic acid; and lubricants such as magnesium stearate and polyethylene glycol.

[0092] Furthermore, the tablets may be, if necessary, coated with a conventional tablet coating, for example, sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, or double-layered or multi-layered tablets.

[0093] A wide variety of known carriers can be used for forming the tablets into pills, including, for example, excipients such as glucose; binders such as powdered gum arabic; and disintegrants such as laminaran.

[0094] Diluents used in forming the liquid, emulsion, and suspension can be any of a wide variety of known diluents, such as water, etc. In addition, ordinary solubilizing agents, buffers, etc. may be contained, and further colorants, preservatives, fragrances, flavorings, sweeteners, and other pharmaceuticals may be contained as necessary.

[0095] As the carrier used for forming the suppository, a wide variety of known carriers can be used, for example, cacao butter.

[0096] When prepared as an injection, the solution, emulsion, or suspension is preferably sterilized and isotonic with blood. The injection may contain sufficient salt or the like to adjust the injection to an isotonic state, and may also contain analgesics or other medicines.

[0097] The amount of the compound [I] of the present invention or a salt thereof contained in the medical preparation is not particularly limited and can be appropriately selected from a wide range, but it is usually preferable that the medical preparation contains the compound [I] of the present invention or a salt thereof in an amount of 1 to 70% by weight.

[0098] The method of administration of the medical preparation according to the present invention is not particularly limited, and may be administered according to various preparation forms, the age, sex, disease state, and other conditions of the patient. For example, tablets, pills, liquids, suspensions, emulsions, granules, and capsules may be administered orally. In the case of injections, they may be administered intravenously alone or in combination with normal replacement fluids such as glucose and amino acids, or may be administered intramuscularly, intradermally, subcutaneously, or intraperitoneally alone as necessary. In the case of suppositories, they may be administered rectally.

[0099] The dosage of the above medical preparation may be appropriately selected depending on the method of use, the patient's age, sex, the severity of the disease, and other conditions, and may usually be administered at 0.01 to 100 mg, preferably 0.1 to 50 mg, per kg of body weight per day, once or in divided doses.

[0100] The above dosage varies depending on various conditions, and therefore, in some cases, a dosage less than the above range is sufficient, and in other cases, a dosage exceeding the above range is required.

[0101] The compound [I] or a salt thereof of the present invention can be used in combination with various therapeutic or prophylactic agents for diseases for which the above-mentioned compound [I] is considered to be effective. The combination may be administered simultaneously, or separately, consecutively, or at a desired time interval. The preparations for simultaneous administration may be formulated as a combination drug or separately.

[0102] In one embodiment of the present invention, there is provided a pharmaceutical composition comprising compound [I] of the present invention or a salt thereof and a pharma- ceutically acceptable carrier and / or excipient.

[0103] In another aspect, there is provided an agent for treating, preventing and / or diagnosing seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising the compound [I] of the present invention or a salt thereof and a pharma- ceutically acceptable carrier and / or excipient.

[0104] In yet another aspect, there is provided a pharmaceutical composition for the treatment, prevention and / or diagnosis of seizures in diseases accompanied by epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising compound [I] of the present invention or a salt thereof and a pharma- ceutically acceptable carrier and / or excipient.

[0105] In yet another aspect, there is provided a method for treating, preventing and / or diagnosing seizures in diseases accompanied by epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising administering to a human an effective amount of compound [I] of the present invention or a salt thereof.

[0106] In yet another aspect, there is provided a compound [I] or a salt thereof of the present invention for treating, preventing and / or diagnosing seizures in diseases involving epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus).

[0107] In yet another aspect, there is provided use of compound [I] of the present invention or a salt thereof in the manufacture of a medicament for treating, preventing and / or diagnosing seizures in diseases involving epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus). EXAMPLES

[0108] The present invention will be further explained in detail by the following Reference Examples, Examples and Test Examples, but these do not limit the present invention and may be modified without departing from the scope of the present invention. The following abbreviations may be used in this specification:

[0109] TIFF2024160219000023.tif227160 TIFF2024160219000024.tif213160

[0110] In the following examples, "room temperature" generally refers to about 10° C. to about 35° C. Ratios shown in mixed solvents are volume ratios unless otherwise specified. % refers to weight % unless otherwise specified. 1 HNMR (proton nuclear magnetic resonance spectrum) was measured by Fourier transform NMR (either Bruker AVANCE III 400 (400 MHz) or Bruker AVANCE III HD (500 MHz)). In silica gel column chromatography, aminopropylsilane-bonded silica gel was used when basic was mentioned. The absolute configuration of the compound was determined by a known X-ray crystal structure analysis method (for example, Shigeru Ohba and Shigenobu Yano, "Basic Lectures for Chemists 12: X-ray Crystal Structure Analysis" (1st edition, 1999)), or was estimated from the empirical rule of asymmetric epoxidation (Waldemar Adam, Rainer T. Fell, Chantu R. Saha-Moller and Cong-Gui Zhao: Tetrahedron: Asymmetry 1998, 9, 397-401; Yuanming Zhu, Yong Tu, Hongwu Yu, Yian Shi: Tetrahedron Lett. 1988, 29, 2437-2440).

[0111] [Reference example] Reference example 1 Synthesis of 5-bromo-2-phenoxypyrimidine 5-Bromo-2-chloropyrimidine (25.0 g) was added to a suspension of phenol (13.6 mL), K2CO3 (26.8 g), and DMF (250 mL), and the mixture was stirred at room temperature overnight. Water was added to the reaction solution, and the resulting crystals were filtered and washed with water to obtain the target compound (27.7 g).

[0112] Reference example 2 Synthesis of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine A mixture of 5-bromo-2-phenoxypyrimidine (1.00 g), (BPin)2 (1.315 g), PdCl2(dppf)DCM (0.163 g), AcOK (0.782 g), and 1,4-dioxane (10 mL) was heated under reflux for 10 hours under a nitrogen atmosphere. Water and AcOEt were added to the reaction solution, and the mixture was filtered through Celite. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was suspended in IPE, insoluble matter was removed by filtration, and the filtrate was concentrated to obtain a solid, which was then washed with hexane to obtain the target compound (646 mg).

[0113] Reference example 18 Synthesis of 3-methoxy-6-(2-(methylthio)pyrimidin-5-yl)pyridazine A mixture of 3-chloro-6-methoxypyridazine (206.3 mg), 2-(methylthio)pyrimidinyl-5-boronic acid pinacol ester (425.4 mg), K3PO4 (663.4 mg), PdCl2(dppf)DCM (48.6 mg), 1,4-dioxane (20 mL), and water (2 mL) was heated under reflux for 1.5 hours under a nitrogen atmosphere. The reaction solution was concentrated, and the residue was purified by silica gel chromatography (Hexane / AcOEt) to obtain the target compound (242.6 mg).

[0114] Reference example 19 Synthesis of 3-methoxy-6-(2-(methylsulfonyl)pyrimidin-5-yl)pyridazine A mixture of 3-methoxy-6-(2-(methylthio)pyrimidin-5-yl)pyridazine (242.6 mg), aqueous 77% m-CPBA (627.9 mg), and DCM (20 mL) was stirred at 0°C for 1 hour and then at room temperature overnight. The reaction mixture was poured into ice and saturated aqueous NaHCO3 solution, and the product was extracted with DCM. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt) to obtain the target compound (166.7 mg).

[0115] Reference example 21 Synthesis of 5-(2-(methylthio)pyrimidin-5-yl)pyridin-2-amine A mixture of 2-(methylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.96 g), 2-amino-5-bromopyridine (1.037 g), K3PO4 (3.86 g), PdCl2(dppf)DCM (273.3 mg), 1,4-dioxane (30 mL), and water (3 mL) was heated under reflux for 6 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was dried over anhydrous sodium sulfate and then concentrated. The residue was purified by basic silica gel chromatography (Hexane / AcOEt) to obtain the target compound (1.175 g).

[0116] Reference example 22 Synthesis of 5-(2-(methylsulfinyl)pyrimidin-5-yl)pyridin-2-amine A mixture of 5-(2-(methylthio)pyrimidin-5-yl)pyridin-2-amine (1.175 g), Oxone® (2.43 g), THF (30 mL), and water (10 mL) was stirred at 0° C. for 10 minutes under nitrogen atmosphere, and then stirred at room temperature for 2.75 hours. The reaction mixture was poured into ice and saturated aqueous NaHCO3 solution, and the product was extracted with DCM. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel chromatography (AcOEt, AcOEt / MeOH) to obtain the target compound (462 mg).

[0117] Reference example 23 Synthesis of 5-bromo-2-(dodecylthio)pyrimidine A mixture of 5-bromo-2-chloropyrimidine (2.30 g), 1-dodecanethiol (3.2 mL), K2CO3 (2.57 g), and DMF (20 mL) was stirred at room temperature overnight. Water was added, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt) to obtain the target compound (3.56 g).

[0118] Reference example 24 Synthesis of 5-(2-(dodecylthio)pyrimidin-5-yl)pyridin-2-amine A mixture of 5-bromo-2-(dodecylthio)pyrimidine (1.008 g), 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (811.6 mg), K3PO4 (1.82 g), PdCl2(dppf)DCM (107.7 mg), 1,4-dioxane (20 mL), and water (2 mL) was heated under reflux for 2.25 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was dried over anhydrous sodium sulfate and then concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt) to obtain the target compound (1.01 g).

[0119] Reference example 25 Synthesis of 5-(2-(dodecylsulfinyl)pyrimidin-5-yl)pyridin-2-amine A mixture of 5-(2-(dodecylthio)pyrimidin-5-yl)pyridin-2-amine (1.010 g), Oxone® (1.97 g), THF (40 mL), and water (10 mL) was stirred at 0° C. for 25 minutes, and then stirred at room temperature overnight. The reaction solution was poured into a mixture of ice, saturated aqueous NaHCO3 solution, and DCM, and extracted with DCM. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt) to obtain the target compound (163 mg).

[0120] Reference example 26 Synthesis of 3-(benzyloxy)-6-(2-phenoxypyrimidin-5-yl)pyridazine A mixture of 5-bromo-2-phenoxypyrimidine (2.96 g), (BPin)2 (3.68 g), PdCl2(dppf)DCM (0.370 g), AcOK (1.78 g), and 1,4-dioxane (20 mL) was heated under reflux for 3 hours under a nitrogen atmosphere. 3-(benzyloxy)-6-chloropyridazine (2.00 g), PdCl2(dppf)DCM (0.370 g), K3PO4 (3.85 g), and water (5 mL) were added to the reaction solution and heated under reflux for 2 hours. Water and AcOEt were added to the reaction solution and the mixture was filtered through Celite. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt), and the obtained solid was washed with AcOEt to obtain the target compound (2.54 g).

[0121] Reference example 35 Synthesis of 4-(2-phenoxypyrimidin-5-yl)-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.496 g), 4-bromo-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one (1.00 g), PdCl2(dppf)DCM (0.063 g), K3PO4 (1.229 g), 1,4-dioxane (10 mL), and water (3 mL) was stirred at 100°C overnight. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt), and the obtained solid was washed with EtOH to obtain the target compound (1.087 g).

[0122] Reference example 38 Synthesis of 5-bromo-1-triisopropylsilyl-1H-pyrazolo[3,4-b]pyridine A solution of 5-bromo-1H-pyrazolo[3,4-b]pyridine (4.20 g) in DMF (20 mL) was added with 60% NaH (0.933 g) under stirring at 0°C. After 20 minutes, chlorotriisopropylsilane (4.99 mL) was added and stirred for 30 minutes. The reaction solution was poured into ice water, and the precipitated solid was collected by filtration. The solid was dissolved in AcOEt, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (6.70 g).

[0123] Reference example 39 Synthesis of 4-methoxy-2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine A mixture of 5-bromo-4-methoxy-2-phenoxypyrimidine (15.00 g), (BPin)2 (14.9 g), AcOK (10.5 g), PdCl2(dppf)DCM (2.18 g), and DMSO (60 mL) was stirred at 100°C for 3 hours under a nitrogen atmosphere. The reaction solution was poured into ice water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt) to obtain the target compound (9.61 g).

[0124] Reference example 40 Synthesis of 2-(dodecylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine A mixture of 5-bromo-2-(dodecylthio)pyrimidine (2.548 g), (BPin)2 (2.17 g), AcOK (1.48 g), PdCl2(dppf)DCM (280.1 mg), and DMSO (20 mL) was stirred at 100°C for 2 hours under a nitrogen atmosphere. The reaction solution was poured into ice water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (1.90 g).

[0125] Reference example 41 Synthesis of 6-(2-(dodecylthio)pyrimidin-5-yl)imidazo[1,2-a]pyridine A mixture of 2-(dodecylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (3.00 g), 6-bromoimidazo(1,2-a)pyridine (1.53 g), PdCl2(dppf)DCM (0.301 g), K3PO4 (3.13 g), 1,4-dioxane (20 mL), and water (10 mL) was stirred at 95°C for 1 hour. The reaction solution was poured into ice water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt) to obtain the target compound (2.05 g).

[0126] Reference example 42 Synthesis of 6-(2-(dodecylsulfonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridine A mixture of 6-(2-(dodecylthio)pyrimidin-5-yl)imidazo[1,2-a]pyridine (2.00 g), Oxone® (7.75 g), THF (40 mL), and water (20 mL) was stirred at room temperature for 5 hours. The reaction solution was poured into ice water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt) to obtain the target compound (910 mg).

[0127] Reference example 43 Synthesis of 5-nitro-2-phenoxypyrimidine A mixture of phenol (6.61 mL), potassium carbonate (12.99 g), 2-chloro-5-nitropyrimidine (10 g), and DMF (80 mL) was stirred at room temperature overnight. Water was added to the reaction solution, and the resulting crystals were filtered and washed with water to obtain the target compound (6.55 g).

[0128] Reference example 44 Synthesis of 2-phenoxypyrimidin-5-amine 5-Nitro-2-phenoxypyrimidine (7.45 g) and aqueous 10% Pd / C (3 g) were suspended in EtOH (100 mL) and stirred under hydrogen atmosphere at room temperature for 4 hours. The reaction mixture was filtered through Celite, the filtrate was concentrated, and the obtained solid was washed with IPE to obtain the target compound (4.73 g).

[0129] Reference example 45 Synthesis of 1-(3-chloropropyl)-3-(2-phenoxypyrimidin-5-yl)urea To a solution of 2-phenoxypyrimidin-5-amine (1.00 g) in THF (10 mL), 3-chloropropyl isocyanate (0.713 mL) was added at room temperature under stirring, and the mixture was stirred overnight. The precipitated solid was collected by filtration and washed with THF to obtain the target compound (756 mg).

[0130] Reference example 46 Synthesis of 2-(3-fluoromethoxyphenoxy)-5-nitropyrimidine A mixture of m-fluorophenol (5.45 mL), potassium carbonate (10.40 g), 2-chloro-5-nitropyrimidine (8.00 g), and DMF (80 mL) was stirred at room temperature overnight. Water was added to the residue, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound (8.63 g).

[0131] Reference example 47 Synthesis of 2-(3-fluorophenoxy)pyrimidin-5-amine 2-(3-Fluoromethoxyphenoxy)nitropyrimidine (8.65 g) and 50% water-containing 10% Pd / C (3 g) were suspended in EtOH (100 mL) and stirred under hydrogen atmosphere at room temperature for 16 hours. The reaction solution was filtered through Celite, and the filtrate was concentrated. The residue was purified by medium pressure column chromatography (DCM / AcOEt), and the obtained solid was washed with hexane to obtain the target compound (3.77 g).

[0132] Reference example 50 Synthesis of 2-phenoxy-5-(4-(triisopropylsilyloxy)piperidin-1-yl)pyrimidine A mixture of 5-bromo-2-phenoxypyrimidine (400 mg), 4-(triisopropylsilyloxy)piperidine (451 mg), Pd(OAc)2 (17.9 mg), tBu3P·HBF4 (23.1 mg), NaOtBu (153 mg) and toluene (6 mL) was stirred at 100°C under nitrogen atmosphere for 3 hours. The reaction solution was filtered through Celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (250 mg).

[0133] Reference example 56 Synthesis of (R)-1-(2-phenoxypyrimidin-5-yl)-4-(triisopropylsilyloxy)piperidin-2-one A mixture of 5-iodo-2-phenoxypyrimidine (500 mg), (R)-4-(triisopropylsilyloxy)piperidin-2-one (501 mg), copper(I) iodide (5.68 μl), trans-N,N'-dimethylcyclohexane-1,2-diamine (0.053 mL), K3PO4 (712 mg) and 1,4-dioxane (6 mL) was stirred at 95°C for 3 hours under a nitrogen atmosphere. The reaction solution was filtered through Celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (340 mg).

[0134] Reference example 58 Synthesis of 1-fluoro-3-(4-nitrophenoxy)benzene A mixture of m-fluorophenol (41.7 g), 4-fluoronitrobenzene (50.0 g), K2CO3 (63.7 g) and DMF (250 mL) was stirred for 6 hours at 80° C. The reaction solution was poured into ice water, and the precipitate was collected by filtration and washed with water to obtain the target compound (80.7 g).

[0135] Reference example 59 Synthesis of 4-(3-fluorophenoxy)aniline A mixture of 1-fluoro-3-(4-nitrophenoxy)benzene (30 g), ammonium chloride (41.3 g), EtOH (225 mL) and water (75 mL) was stirred at room temperature, zinc powder (50.5 g) was added, and the mixture was further stirred at 60°C for 1 hour. Insoluble matter was filtered through Celite, the filtrate was concentrated, and the residue was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (26 g).

[0136] Reference example 60 Synthesis of 1-(4-bromophenyl)dihydropyrimidine-2,4(1H,3H)-dione A solution of 4-bromoaniline (7.66 g) and acrylic acid (3.05 mL) in toluene (50 mL) was stirred overnight at 80° C. The reaction mixture was concentrated, and urea (5.35 g) and acetic acid (20 mL) were added and the mixture was heated to reflux for 3 hours. The precipitated solid was collected by filtration and washed with EtOH to obtain the target compound (5.44 g).

[0137] Reference example 61 Synthesis of 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione A mixture of 1-(4-bromophenyl)dihydropyrimidine-2,4(1H,3H)-dione (2.78 g), (BPin)2 (3.15 g), AcOK (3.04 g), PdCl2(dppf)DCM (0.422 g), and DMSO (30 mL) was stirred at 100°C for 5 hours under an argon atmosphere. The reaction solution was poured into ice water and extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH) to obtain the target compound (0.82 g).

[0138] Reference example 76 Synthesis of 1-[4-(3-hydroxyphenoxy)phenyl]dihydropyrimidine-2,4(1H,3H)-dione To a solution of 1-[4-(3-methoxyphenoxy)phenyl]dihydropyrimidine-2,4(1H,3H)-dione (3.86 g) in AcOH (25 mL), HBr (12.5 mL) was added under ice cooling and stirred for 3 hours. Water (100 mL) was added to the reaction solution and stirred, and the precipitated crystals were collected by filtration. After washing with water and drying, the product was purified by silica gel column chromatography (DCM / MeOH), and the obtained solid was washed with MeOH to obtain the target compound (1.11 g).

[0139] Reference example 77 Synthesis of 3-(3-fluorophenoxy)aniline A mixture of 3-fluoroiodobenzene (0.587 mL), 3-aminophenol (818 mg), K3PO4 (2.12 g), picolinic acid (123 mg), copper(I) iodide (95 mg), and DMSO (15 mL) was stirred at 90°C for 24 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (865 mg).

[0140] Reference example 83 Synthesis of 5-nitro-2-phenoxypyridine A solution of 2-chloro-5-nitropyridine (16.0 g) in DMF (80 mL) was added with sodium phenoxide (12.3 g) under ice-cooling and stirring, and the mixture was stirred at room temperature overnight. The reaction solution was poured into ice water, and the precipitated crystals were collected by filtration and washed with water to obtain the target compound (21.1 g).

[0141] Reference example 84 Synthesis of 6-phenoxypyridin-3-amine A mixture of 5-nitro-2-phenoxypyridine (21 g), 10% Pd / C (2 g) and EtOH (200 mL) was stirred under hydrogen atmosphere at room temperature for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (15 g).

[0142] Reference example 111 Synthesis of 1-(6-chloropyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione A mixture of 3,6-dichloropyridazine (10.00 g), uracil (8.28 g), and DMSO (100 mL) was stirred overnight at 70° C. Water was added to the reaction solution, and the resulting solid was collected by filtration and washed with water and EtOH to obtain the target compound (9.51 g).

[0143] The compounds of Reference Examples 3 to 17, 20, 27 to 34, 36, 37, 48, 49, 51 to 55, 57, 62 to 75, 78 to 82, 85 to 95 and 97 to 110 were produced in the same manner as in Reference Examples 1, 2, 18, 19, 21 to 26, 35, 38 to 47, 50, 56, 58 to 61, 76, 77, 83, 84 and 111. The structural formulas and physical property data of the compounds of Reference Examples 1 to 111 are shown in Tables 1-1 to 1-11, respectively.

[0144]

Table 1-1

Table 1-2

Table 1-3

Table 1-4

Table 1-5

Table 1-6

Table 1-7

Table 1-8

Table 1-9

[0145] Example 1 Synthesis of 3-methoxy-6-(2-phenoxypyrimidin-5-yl)pyridazine A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (5.00 g), 3-chloro-6-methoxypyridazine (3.64 g), PdCl2(dppf)DCM (0.137 g), K3PO4 (7.12 g), 1,4-dioxane (50 mL), and water (25 mL) was heated under reflux for 2 hours under a nitrogen atmosphere. The reaction solution was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt) to obtain the target compound (4.42 g).

[0146] Example 4 Synthesis of 3-(2-(3-fluorophenoxy)pyrimidin-5-yl)-6-methoxypyridazine A mixture of 5-bromo-2-(3-fluorophenoxy)pyrimidine (2.234 g), (BPin)2 (2.63 g), PdCl2(dppf)DCM (0.282 g), AcOK (1.358 g), and 1,4-dioxane (20 mL) was heated under reflux for 2 hours under a nitrogen atmosphere. 3-Chloro-6-methoxypyridazine (1.00 g), PdCl2(dppf)DCM (0.282 g), K3PO4 (2.94 g), and water (5 mL) were added to the reaction solution, and the mixture was heated under reflux overnight under a nitrogen atmosphere. Water and AcOEt were added to the reaction solution, and the mixture was filtered through Celite, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The precipitated crystals were washed with EtOH to obtain the target compound (947 mg).

[0147] Example 6 Synthesis of 5-(6-methoxypyridin-3-yl)-2-phenoxypyrimidine A mixture of 5-bromo-2-phenoxypyrimidine (1.0 g), 2-methoxy-5-pyridineboronic acid (0.914 g), PdCl2(dppf)DCM (0.163 g), K3PO4 (1.691 g), 1,4-dioxane (10 mL), and water (5 mL) was heated under reflux for 2 hours under a nitrogen atmosphere. The reaction mixture was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt), and the obtained solid was washed with EtOH to obtain the target compound (821 mg).

[0148] Example 7 Synthesis of 2-phenoxy-5-(pyridin-3-yl)pyrimidine A mixture of 5-bromo-2-phenoxypyrimidine (1.0 g), 3-pyridineboronic acid (0.734 g), PdCl2(dppf)DCM (0.163 g), K3PO4 (1.691 g), 1,4-dioxane (10 mL), and water (5 mL) was heated under reflux for 2 hours under a nitrogen atmosphere. The reaction mixture was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt), and the obtained solid was washed with EtOH to obtain the target compound (386 mg).

[0149] Example 11 Synthesis of 3-(2-phenoxypyrimidin-5-yl)pyridine 1-oxide A mixture of 2-phenoxy-5-(pyridin-3-yl)pyrimidine (749 mg), 77% m-CPBA (1616 mg), and DCM (15 mL) was stirred at room temperature overnight. Dimethyl sulfide (309 μl) was added to the reaction mixture and stirred for a while, and then a saturated aqueous NaHCO3 solution was added, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt), and the obtained solid was washed with AcOEt to obtain the target compound (118 mg).

[0150] Example 24 Synthesis of 6-(2-(3-fluorophenoxy)pyrimidin-5-yl)pyridazin-3-amine A mixture of 2-(3-fluorophenoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (581 mg), 3-amino-6-chloropyridazine (202 mg), K3PO4 (1.11 g), PdCl2(dppf)DCM (68 mg), 1,4-dioxane (20 mL), and water (2 mL) was heated under reflux for 2 hours under nitrogen atmosphere. The reaction solution was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt, AcOEt / MeOH), and the obtained solid was washed with IPE to obtain the target compound (100 mg).

[0151] Example 30 Synthesis of 6-(2-phenoxypyrimidin-5-yl)pyridazin-3-amine A mixture of 3-amino-6-chloropyridazine (205 mg), 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (526 mg), K3PO4 (1.11 g), PdCl2(dppf)DCM (65.2 mg), 1,4-dioxane (10 mL), and water (2 mL) was heated under reflux for 5.5 hours under nitrogen atmosphere. The reaction solution was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt, AcOEt / MeOH) to obtain the target compound (180 mg).

[0152] Example 36 Synthesis of 5-(2-phenoxypyrimidin-5-yl)pyridin-2-amine A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (386 mg), 2-amino-5-bromopyridine (209 mg), K3PO4 (1.0 g), PdCl2(dppf)DCM (43.7 mg), 1,4-dioxane (20 mL), and water (2 mL) was heated under reflux for 2.75 hours under a nitrogen atmosphere. The reaction solution was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt), and the obtained solid was washed with IPE to obtain the target compound (161 mg).

[0153] Example 38 Synthesis of 3-(2-phenoxypyrimidin-5-yl)-6-(trifluoromethyl)pyridazine A mixture of 3-chloro-6-(trifluoromethyl)pyridazine (209 mg), 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (373 mg), K3PO4 (780 mg), PdCl2(dppf)DCM (29.3 mg), 1,4-dioxane (20 mL), and water (2 mL) was heated under reflux for 5 hours under a nitrogen atmosphere. The reaction solution was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt), and the obtained solid was washed with AcOEt to obtain the target compound (107 mg).

[0154] Example 60 Synthesis of 3-(2-(2-fluorophenoxy)pyrimidin-5-yl)pyridine 1-oxide A mixture of 3-(2-(2-fluorophenoxy)pyrimidin-5-yl)pyridine (998 mg), aqueous 77% m-CPBA (1255 mg), and DCM (15 mL) was stirred at room temperature overnight. Dimethyl sulfide and saturated aqueous NaHCO3 were added to the reaction mixture, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (AcOEt / MeOH), and the obtained solid was washed with EtOH to obtain the target compound (383 mg).

[0155] Example 63 Synthesis of 3-(2-(2,5-difluorophenoxy)pyrimidin-5-yl)-6-methoxypyridazine A mixture of 2,5-difluorophenol (132 mg), 3-methoxy-6-(2-(methylsulfonyl)pyrimidin-5-yl)pyridazine (167 mg), K2CO3 (176 mg), and DMF (5 mL) was stirred at room temperature for 2 hours. Water was added to the reaction solution, and the precipitated crystals were collected by filtration to obtain the target compound (187 mg).

[0156] Example 69 Synthesis of 2-(6-(2-phenoxypyrimidin-5-yl)pyridazin-3-yl)propan-2-ol Ethyl 6-(2-phenoxypyrimidin-5-yl)pyridazine-3-carboxylate (200 mg) was suspended in THF (3 mL), and then 0.96M methylmagnesium bromide in THF (1.6 mL) was added under ice cooling and stirred at room temperature overnight. The reaction solution was poured into a saturated aqueous ammonium chloride solution, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt), and the obtained solid was washed with IPE to obtain the target compound (45 mg).

[0157] Example 72 Synthesis of (6-(2-phenoxypyrimidin-5-yl)pyridazin-3-yl)methanol A mixture of calcium chloride (551 mg), NaBH4 (117 mg), THF (2 mL), and EtOH (2 mL) was added with ethyl 6-(2-phenoxypyrimidin-5-yl)pyridazine-3-carboxylate (400 mg) under ice cooling and stirred for 30 minutes. Aqueous citric acid was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt), and the obtained solid was washed with IPE to obtain the target compound (81 mg).

[0158] Example 84 Synthesis of 5-(2-(2,5-difluorophenoxy)pyrimidin-5-yl)pyridin-2-amine A mixture of 5-(2-(methylsulfinyl)pyrimidin-5-yl)pyridin-2-amine (100 mg), 2,5-difluorophenol (130 mg), K2CO3 (236 mg), and DMF (7 mL) was stirred at 80°C under a nitrogen atmosphere for 3.5 hours. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by basic silica gel chromatography (Hexane / AcOEt), and the obtained solid was washed with Hexane / IPE to obtain the target compound (44 mg).

[0159] Example 88 Synthesis of 5-(2-(m-tolyloxy)pyrimidin-5-yl)pyridin-2-amine A mixture of 5-(2-(dodecylsulfinyl)pyrimidin-5-yl)pyridin-2-amine (163 mg), m-cresol (0.10 mL), K2CO3 (483 mg), and DMF (10 mL) was stirred at 80°C for 4 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by basic silica gel chromatography (Hexane / AcOEt), and the obtained solid was washed with IPE to obtain the target compound (50 mg).

[0160] Example 91 Synthesis of 6-(2-phenoxypyrimidin-5-yl)pyridazin-3(2H)-one A mixture of 3-(benzyloxy)-6-(2-phenoxypyrimidin-5-yl)pyridazine (2.54 g), 10% Pd / C (2 g), EtOH (25 mL), and THF (75 mL) was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated. The residue was crystallized from EtOH to give the desired compound (1.38 g).

[0161] Example 92 Synthesis of 6-(2-phenoxypyrimidin-5-yl)-4,5-dihydropyridazin-3(2H)-one A mixture of 6-(2-phenoxypyrimidin-5-yl)pyridazin-3(2H)-one (1.08 g), zinc powder (0.53 g), and AcOH (10 mL) was heated to reflux for 1 hour. The reaction solution was concentrated, water was added to the residue, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH) and washed with EtOH to obtain the target compound (583 mg).

[0162] Example 94 Synthesis of 6-(2-(3-fluorophenoxy)pyrimidin-5-yl)-4,5-dihydropyridazin-3(2H)-one A mixture of 6-(2-(3-fluorophenoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (1.02 g), zinc powder (0.56 g), and AcOH (10 mL) was heated to reflux for 3 hours. The reaction solution was concentrated, water was added to the residue, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt), and the obtained solid was washed with EtOH to obtain the target compound (587 mg).

[0163] Example 106 Synthesis of 5-(2-(m-tolyloxy)pyrimidin-5-yl)pyridin-2(1H)-one A mixture of 5-(6-methoxypyridin-3-yl)-2-(m-tolyloxy)pyrimidine (425 mg), sodium iodide (652 mg), chlorotrimethylsilane (0.552 mL), and MeCN (5 mL) was stirred at room temperature overnight. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH) and crystallized from EtOH to obtain the target compound (204 mg).

[0164] Example 114 Synthesis of 4-(2-phenoxypyrimidin-5-yl)pyridazin-3(2H)-one A mixture of 4-(2-phenoxypyrimidin-5-yl)-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one (1.085 g), TFA (10 mL), and DCM (10 mL) was stirred at room temperature for 1 hour. The reaction mixture was concentrated, and the residue was neutralized with saturated aqueous NaHCO3 solution, and the product was extracted with DCM. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt), and the obtained solid was washed with EtOH to obtain the target compound (672 mg).

[0165] Example 118 Synthesis of 4-(2-phenoxypyrimidin-5-yl)quinoline A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (500 mg), 4-bromoquinoline (419 mg), K3PO4 (712 mg), PdCl2(dppf)DCM (13.70 mg), 1,4-dioxane (5 mL), and water (2.5 mL) was heated under reflux for 1.5 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was dried over anhydrous sodium sulfate and then concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt), and the obtained solid was washed with IPE to obtain the target compound (413 mg).

[0166] Example 119 Synthesis of 6-(2-phenoxypyrimidin-5-yl)imidazo[1,2-a]pyridine A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (400 mg), 6-bromo-imidazo[1,2-a]pyridine (291 mg), PdCl2(dppf)DCM (110 mg), K3PO4 (570 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 100°C for 3 hours under a nitrogen atmosphere. AcOEt and water were added to the reaction solution, and the mixture was filtered through Celite. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by basic silica gel column chromatography (DCM / AcOEt) to obtain the target compound (318 mg).

[0167] Example 123 Synthesis of 6-(2-phenoxypyrimidin-5-yl)imidazo[1,2-b]pyridazine A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (400 mg), 6-chloro-imidazo[1,2-b]pyridazine (227 mg), PdCl2(dppf)DCM (110 mg), K3PO4 (570 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 95°C for 3 hours under a nitrogen atmosphere. AcOEt and water were added to the reaction solution, and the mixture was filtered through Celite. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by basic silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (329 mg).

[0168] Example 137 Synthesis of 6-(2-phenoxypyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridine A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (400 mg), 6-bromo-1-(triisopropylsilyl)-1H-pyrrolo[3,2-b]pyridine (522 mg), PdCl2(dppf)DCM (110 mg), K3PO4 (570 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 90°C for 3 hours under a nitrogen atmosphere. AcOEt and water were added to the reaction solution, and the mixture was filtered through Celite. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was dissolved in THF (5 mL), 1N-TBAF (1.34 mL) was added, and the mixture was stirred at room temperature for 1 hour, and the reaction solution was concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (DCM / AcOEt) to obtain the target compound (325 mg).

[0169] Example 139 Synthesis of 4-(2-phenoxypyrimidin-5-yl)-1,8-naphthyridine A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (300 mg), 4-chloro-[1,8]naphthyridine (199 mg), K3PO4 (427 mg), PdCl2(dppf)DCM (6.56 mg), 1,4-dioxane (4 mL), and water (2 mL) was heated under reflux for 3 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (MeOH / DCM), and the obtained solid was recrystallized from AcOEt to obtain the target compound (167 mg).

[0170] Example 163 Synthesis of 6-(2-(3-chlorophenoxy)pyrimidin-5-yl)imidazo[1,2-a]pyridine A mixture of 6-(2-(dodecylsulfonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridine (300 mg), 1-chloro-3-hydroxybenzene (0.089 mL), K2CO3 (193 mg), and DMF (3 mL) was stirred at 80°C for 5 hours. The reaction solution was poured into ice water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by basic column chromatography (DCM / AcOEt) to obtain the target compound (194 mg).

[0171] Example 172 Synthesis of 5-(2-phenoxypyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-2(3H)-one A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (560 mg), 5-bromo-1H,2H,3H-pyrrolo[3,2-b]pyridin-2-one (200 mg), PdCl2(dppf)DCM (38.3 mg), K3PO4 (399 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 90°C for 5 hours under a nitrogen atmosphere. AcOEt and water were added to the reaction solution, and the mixture was filtered through Celite. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by basic silica gel column chromatography (DCM / AcOEt) to obtain the target compound (98 mg).

[0172] Example 173 Synthesis of 6-(2-phenoxypyrimidin-5-yl)-[1,2,3]triazolo[1,5-a]pyridine A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (330 mg), 6-bromo-[1,2,3]triazolo[1,5-a]pyridine (241 mg), PdCl2(dppf)DCM (45.2 mg), K3PO4 (470 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 90°C for 5 hours. AcOEt and water were added to the reaction solution, and the mixture was filtered through Celite. The filtrate was separated, and the organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by basic silica gel column chromatography (DCM / AcOEt) to obtain the target compound (250 mg).

[0173] Example 198 Synthesis of 5-methyl-6-(2-phenoxypyrimidin-5-yl)imidazo[1,2-a]pyridine hydrochloride A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (330 mg), 6-bromo-5-methyl-imidazo[1,2-a]pyridine (257 mg), PdCl2(dppf)DCM (45.2 mg), K3PO4 (470 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 90°C for 5 hours. AcOEt and water were added to the reaction solution, and the mixture was filtered through Celite. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by basic silica gel column chromatography (DCM / AcOEt). The obtained oily substance was dissolved in EtOH, and 3 mL of 1N-HCl EtOH solution was added and stirred, and the reaction solution was concentrated. The precipitated crystals were recrystallized from EtOH / AcOEt to obtain the target compound (349 mg).

[0174] Example 220 Synthesis of 1-(2-phenoxypyrimidin-5-yl)tetrahydropyrimidin-2(1H)-one A solution of 1-(3-chloropropyl)-3-(2-phenoxypyrimidin-5-yl)urea (1.25 g) in DMF (12 mL) was added with 60% NaH (0.148 g) under ice-cooling and stirring, and the mixture was stirred at room temperature for 2 days. Water was added to the residue, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The precipitated crystals were washed with EtOH to obtain the target compound (181 mg).

[0175] Example 221 Synthesis of 1-(2-(3-fluorophenoxy)pyrimidin-5-yl)tetrahydropyrimidin-2(1H)-one 2-(3-Fluorophenoxy)pyrimidin-5-amine (1.00 g) was dissolved in THF (10 mL) and DMF (10 mL), 3-chloropropyl isocyanate (0.800 mL) was added, and the mixture was stirred at 50° C. for 3 hours. Water was added to the reaction solution, and the precipitated crystals were collected by filtration to obtain an intermediate (1.41 g). The intermediate was dissolved in DMF (14 mL), and 60% NaH (0.214 g) was added under ice cooling, and the mixture was stirred at room temperature for 1 hour. Ice water was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (AcOEt / MeOH), and the obtained solid was washed with EtOH to obtain the target compound (460 mg).

[0176] Example 223 Synthesis of 2-phenoxy-5-(piperidin-1-yl)pyrimidine A mixture of 5-bromo-2-phenoxypyrimidine (500 mg), piperidine (0.256 mL), Pd(OAc)2 (447 mg), tBu3P·HBF4 (578 mg), NaOtBu (191 mg), and toluene (10 mL) was stirred at 100°C for 1 hour under a nitrogen atmosphere. AcOEt and water were added to the reaction solution, which was then filtered through Celite. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel chromatography (Hexane / AcOEt) to obtain the target compound (53 mg).

[0177] Example 226 Synthesis of 1-(2-phenoxypyrimidin-5-yl)piperidin-4-ol 2-Phenoxy-5-(4-(triisopropylsilyloxy)piperidin-1-yl)pyrimidine (240 mg) in THF (6 mL) was added with TBAF (0.56 mL) and stirred at room temperature for 30 minutes. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (Hexane / AcOEt) and crystallized from Hexane / AcOEt to obtain the target compound (110 mg).

[0178] Example 229 Synthesis of 4-(2-phenoxypyrimidin-5-yl)morpholin-3-one A mixture of 5-iodo-2-phenoxypyrimidine (500 mg), 3-ketomorpholine (254 mg), copper(I) iodide (31.9 mg), K3PO4 (712 mg), (1R,2R)-N,N-dimethyl-1,2-cyclohexanediamine (0.053 mL), and 1,4-dioxane (6 mL) was stirred at 90°C for 4 hours. The reaction solution was filtered through Celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (368 mg).

[0179] Example 239 Synthesis of 4-(2-phenoxypyrimidin-5-yl)aniline A mixture of 5-(4-nitrophenyl)-2-phenoxypyrimidine (3.8 g), 10% Pd / C (0.4 g) and EtOH (80 mL) was stirred at room temperature under a hydrogen atmosphere for 1 hour. The reaction mixture was filtered through Celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (2.5 g) as a white solid.

[0180] Example 240 Synthesis of 6-(2-phenoxypyrimidin-5-yl)benzo[d]thiazol-2-amine A solution of bromine (0.140 mL) in acetic acid (2 mL) was added to a solution of 4-(2-phenoxypyrimidin-5-yl)aniline (600 mg) and ammonium thiocyanate (382 mg) in acetic acid (6 mL) under ice-cooling and stirring. After 1 hour, the reaction solution was poured into ice water, and 28% aqueous ammonia was added until the reaction system became basic, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt) to obtain the target compound (542 mg).

[0181] Example 257 Synthesis of 5-(2-phenoxypyrimidin-5-yl)-1H-benzo[d]imidazole oxalate A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (400 mg), 5-bromo-1H-benzo[d]imidazole (291 mg), PdCl2(dppf)DCM (110 mg), K3PO4 (570 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 95°C for 3 hours under nitrogen atmosphere. AcOEt and water were added to the reaction solution and filtered through Celite. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt). The obtained oily substance was dissolved in ethanol, and an ethanol solution (1 mL) of oxalic acid (80 mg) was added. The precipitate was collected by filtration and dried to obtain the target compound (250 mg).

[0182] Example 262 Synthesis of 5-(2-phenoxypyrimidin-5-yl)-1H-indole A mixture of 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (400 mg), 5-bromo-1-(triisopropylsilyl)-1H-indole (520 mg), PdCl2(dppf)DCM (110 mg), K3PO4 (570 mg), 1,4-dioxane (4 mL), and water (2 mL) was stirred at 80°C for 3 hours under a nitrogen atmosphere. AcOEt and water were added to the reaction solution and filtered through Celite. The filtrate was separated, and the organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was dissolved in THF (10 mL), to which TBAF (1.342 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated and then purified by silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (319 mg).

[0183] Example 302 Synthesis of 1-(4-(3-fluorophenoxy)phenyl)dihydropyrimidine-2,4(1H,3H)-dione A mixture of 4-(3-fluorophenoxy)aniline (5.00 g), acrylic acid (2.53 mL) and toluene (40 mL) was stirred at 80° C. overnight. The reaction mixture was concentrated, and urea (4.43 g) and AcOH (20 mL) were added and the mixture was heated to reflux for 3 hours. Water was added and the precipitate was collected by filtration. The precipitate was purified by silica gel column chromatography (DCM / MeOH) to obtain the target compound (2.33 g).

[0184] Example 305 Synthesis of 1-(4-(3-fluorobenzyl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione A mixture of m-fluorobenzyl chloride (0.11 mL), 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione (0.25 g), K3PO4 (0.252 g), PdCl2(dppf)DCM (6.46 mg), DME (6.6 mL), and water (3.3 mL) was heated under reflux for 2 hours under a nitrogen atmosphere. The reaction solution was poured into ice water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt) to obtain the target compound (30 mg).

[0185] Example 308 Synthesis of 1-(4-(3-fluorophenoxy)phenyl)-3-methyldihydropyrimidine-2,4(1H,3H)-dione A solution of 1-(4-(3-fluorophenoxy)phenyl)dihydropyrimidine-2,4(1H,3H)-dione (200 mg) in DMF (5 mL) was added with 60% NaH (32.0 mg) under stirring at 0°C and stirred for 30 minutes. Methyl iodide (0.046 mL) was added under stirring at 0°C, and the mixture was stirred overnight at room temperature. The reaction solution was poured into ice water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by basic silica gel column chromatography (Hexane / AcOEt) to obtain the target compound (50 mg).

[0186] Example 314 Synthesis of 1-{4-[3-(difluoromethoxy)phenoxy]phenyl}dihydropyrimidine-2,4(1H,3H)-dione A mixture of 1-[4-(3-hydroxy)phenyl]dihydropyrimidine-2,4(1H,3H)-dione (337 mg), sodium chlorodifluoroacetate (344 mg), K2CO3 (234 mg) and DMF (1.7 mL) was stirred at 90°C for 4 hours. Sodium chlorodifluoroacetate (344 mg) was added and stirred for another 2 hours. Hydrochloric acid was added to the reaction solution, and the product was extracted with AcOEt. It was washed with water, an aqueous NaOH solution, and water, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt) and crystallized by adding EtOH. It was washed with EtOH to obtain the target compound (79 mg).

[0187] Example 321 Synthesis of 1-[4-(6-fluoropyridin-2-yloxy)phenyl]dihydropyrimidine-2,4(1H,3H)-dione A mixture of 1-(4-hydroxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (412 mg), 2,6-difluoropyridine (0.218 mL), K2CO3 (553 mg), and DMSO (2 mL) was stirred at 100°C for 2 hours. Water (10 mL) was added to the reaction solution, and the precipitated solid was collected by filtration. The solid was purified by silica gel column chromatography (DCM / MeOH), and the obtained solid was washed with EtOH to obtain the target compound (244 mg).

[0188] Example 322 Synthesis of 1-(4-phenoxyphenyl)pyrimidine-2,4(1H,3H)-dione A mixture of 4-phenoxyphenylboronic acid (1.27 g), uracil (0.798 g), N,N,N',N'-tetramethylethylenediamine (0.896 mL), copper(II) acetate (0.539 g), MeOH (40 mL), and water (10 mL) was stirred at room temperature overnight. The reaction solution was poured into water, and the product was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (DCM / AcOEt) to obtain the target compound (160 mg).

[0189] Example 327 Synthesis of 1-((1,1'-biphenyl)-4-yl)dihydropyrimidine-2,4(1H,3H)-dione A mixture of monobromobenzene (0.158 mL), 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]dihydropyrimidine-2,4(1H,3H)-dione (316 mg), Pd(Ph3P)4 (57.8 mg), Na2CO3 (212 mg), DME (5 mL), and water (1 mL) was heated under reflux for 12 hours under nitrogen atmosphere. AcOEt and anhydrous magnesium sulfate were added to the reaction solution, and the mixture was filtered through Celite. The filtrate was concentrated, and the residue was purified by silica gel chromatography (DCM / MeOH), and the obtained solid was washed with EtOH to obtain the target compound (35 mg).

[0190] Example 328 Synthesis of 6-methyl-1-(4-phenoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione A mixture of 4-phenoxyaniline (0.50 g), toluene (5 mL), and crotonic acid (0.34 mL) was heated to reflux for 13 hours. Crotonic acid (0.34 mL) was added and the mixture was heated to reflux for another 6 hours. The reaction mixture was concentrated, and acetic acid (5 mL) and urea (0.324 g) were added, and the mixture was heated to reflux for 17 hours. Concentrated hydrochloric acid (0.23 mL) was added to the reaction mixture, and the mixture was heated to reflux for 30 minutes. Water was added to the reaction mixture, and the product was extracted with AcOEt. The mixture was washed with water, saturated aqueous NaHCO3 solution, and brine, dried over anhydrous magnesium sulfate, and then concentrated. The residue was crystallized by adding EtOH (3 mL) and IPE (3 mL). The solid was collected by filtration and washed with IPE to obtain the target compound (272 mg).

[0191] Example 337 Synthesis of 6,6-dimethyl-1-(4-phenoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione A mixture of 4-phenoxyaniline (1.0 g) and 3,3-dimethylacrylic acid (2.70 g) was stirred at 70-80°C for 75 hours. Urea (0.648 g) and AcOH (6 mL) were added to the reaction solution, and the mixture was heated to reflux for 5 hours. Water (20 mL) was added to the reaction solution, and then a saturated aqueous NaHCO3 solution was added to neutralize it. After extraction with AcOEt, the mixture was washed with a saturated aqueous NaCl solution, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (Hexane / AcOEt), and the obtained solid was washed with EtOH to obtain the target compound (103 mg).

[0192] Example 343 Synthesis of 6-ethyl-1-(4-phenoxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione A mixture of 4-phenoxyaniline (0.50 g) and trans-2-pentenoic acid (1.37 mL) was stirred at 120°C for 5 hours. AcOH (5 mL) and urea (0.324 g) were added to the reaction solution, and the mixture was heated to reflux for 3 hours. Water and AcOEt were added to the reaction solution and the mixture was separated. The organic layer was washed with a saturated aqueous solution of NaHCO3 and brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH) and crystallized by adding EtOH (2 mL). The solid was collected by filtration and washed with EtOH and IPE to obtain the target compound (204 mg).

[0193] Example 344 Synthesis of 1-[4-(3,5-difluoromethoxy)phenyl]dihydropyrimidine-2,4(1H,3H)-dione A mixture of 1-(4-hydroxyphenyl)dihydropyrimidine-2,4(1H,3H)-dione (330 mg), 1,3,5-trifluorobenzene (0.199 mL), K2CO3 (442 mg), and DMSO (2 mL) was stirred at 100°C for 3.5 hours. 1,3,5-trifluorobenzene (0.199 mL) was added and stirred for another 1.5 hours. Water (15 mL) was added to the reaction solution, and the precipitated solid was collected by filtration and washed with water and EtOH to obtain the target compound (35 mg).

[0194] Example 346 Synthesis of 1-(6-phenoxypyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione A mixture of phenol (1.017 mL), 1-(6-chloropyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione (2.00 g), Cs2CO3 (4.35 g), and DMSO (20 mL) was stirred at 130° C. overnight. Aqueous citric acid was added to the reaction solution, and the product was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The residue was washed with EtOH to obtain the target compound (588 mg).

[0195] Example 347 Synthesis of 1-(6-phenoxypyridazin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione 1-(6-phenoxypyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione (577 mg) was dissolved in DMF (10 mL), and 50% water-containing 10% Pd / C (500 mg) was added and stirred under a hydrogen atmosphere at 50°C for 6 hours. The reaction solution was filtered through Celite, and the filtrate was concentrated. The residue was purified by medium pressure column chromatography (DCM / AcOEt), and the obtained solid was washed with EtOH to obtain the target compound (122 mg).

[0196] In the same manner as in the above Examples 1, 4, 6, 7, 11, 24, 30, 36, 38, 60, 63, 69, 72, 84, 88, 91, 92, 94, 106, 114, 118, 119, 123, 137, 139, 163, 172, 173, 198, 220, 221, 223, 226, 229, 239, 240, 257, 262, 302, 305, 308, 314, 321, 322, 327, 328, 337, 343, 344, 346, and 347, Examples 2, 3, 5, 8 to 10, 12 to 23, 25 to 29, 31 to 35, 37, 39 to 59, 61, 62, Compounds 64-68, 70, 71, 73-83, 85-87, 89, 90, 93, 95-105, 107-113, 115-117, 120-122, 124-136, 138, 140-162, 164-171, 174-197, 199-219, 222, 224, 225, 227, 228, 230-238, 241-256, 258-261, 263-301, 303, 304, 306, 307, 309-313, 315-320, 323-326, 329-336, 338-342, 345 and 348-350 were produced, respectively. The structural formulas and physical property data of the compounds of Examples 1 to 347 are shown in Tables 2-1 to 2-37, respectively.

[0197]

Table 2-1

Table 2-2

Table 2-3

Table 2-4

Table 2-5

Table 2-6

Table 2-7

Table 2-8

Table 2-9

Table 2-10

Table 2-11

Table 2-12

Table 2-13

Table 2-14

Table 2-15

Table 2-16

Table 2-17

Table 2-18

Table 2-19

Table 2-20

Table 2-21

Table 2-22

Table 2-23

Table 2-24

Table 2-25

Table 2-26

Table 2-27

Table 2-28

Table 2-29

Table 2-30

Table 2-31

Table 2-32

Table 2-33

Table 2-34

Table 2-35

Table 2-36

[0198] [Test example] The pharmacological test results of representative compounds of the present invention are shown below, and the pharmacological actions of the compounds are explained, but the present invention is not limited to these test examples.

[0199] [Test Example 1] Audiogenic epilepsy model The animal model used in this study is clinically predictive and has a phenotype of partial seizures (including secondary generalization) and generalized tonic-clonic seizures. This study was performed according to the report by De Sarro et al. (Br J Pharmacol. 1988 Feb; 93(2): 247-56. Anticonvulsant effects of some calcium entry blockers in DBA / 2 mice. De Sarro GB, Meldrum BS, Nistico G.). In this test example, the example compounds shown in the following Tables 3-1 to 3-3 were used as test compounds. The test compound was suspended in 5% gum arabic / distilled water (w / v) and administered orally at a dose of 30 mg / kg to male and female DBA / 2 mice (Japan SLC Co., Ltd., 3 weeks old, 8 mice per group). One hour later, the mice were placed in a transparent acrylic cylinder with a diameter of 23 cm and a height of 30 cm, and after 30 seconds of acclimation, a 12.6 kHz, 100-110 dB sound stimulus was given for 1 minute or until the onset of tonic seizures. The severity of seizures was categorized as 0: no seizure, 1: wild running, 2: clonic seizure, 3: tonic seizure, and 4: respiratory arrest, and the maximum of these points was recorded as the seizure severity score. The seizure inhibition rate for each compound administration group was calculated using the following formula.

number

[0200] [Test Example 2] Rotarod test This test evaluates the synergistic effects of compounds. In this test example, the example compounds shown in Table 4 below were used as test compounds. Male ICR mice (Japan SLC Co., Ltd., 5-6 weeks old, 8 mice per group) were placed on a rotarod apparatus (Muromachi Kikai Co., Ltd.) and trained to walk from a rod rotating at a fixed speed (15 rotations / min) for 2 minutes without falling off. The test compound was suspended in 5% gum arabic / distilled water (w / v) and administered orally at a dose of 30 mg / kg to the trained mice. After 1 hour, the mice were placed on the same rotarod apparatus as above, and observed for 200 seconds to see whether they could walk in time with the rotation of the rod, which accelerated from 4 rotations / min to 40 rotations / min over 5 minutes, and the falling latency was measured. The relative value of the falling latency of the compound-administered group to the average value of the falling latency of the vehicle-administered group was calculated. The results are shown in Tables 4-1 and 4-2. Coordination impairment was designated as "A" if it was 25% or less, and "B" if it was greater than 25% but less than 50%. [Table 4-1] [Table 4-2]

[0201] [Test Example 3] Maximum electric shock convulsion model This test evaluates the anticonvulsant effect of a compound. The animal model used in this test is a phenotype of generalized tonic-clonic seizures and secondarily generalized partial seizures. This test was performed according to the report by Hill AJ et al. (Br J Pharmacol. 2012 Dec;167(8):1629-42. Cannabidivarin is anticonvulsant in mouse and rat. Hill AJ, et al.). The test compound was suspended in 5% gum arabic / distilled water (w / v) and administered orally at a dose of 30 mg / kg to male ICR mice (Japan SLC Co., Ltd., 5-6 weeks old, 8 mice per group). One hour later, electrical stimulation (100 Hz, 30 mA, 0.2 seconds) was administered from electrodes attached to both ears using an electric shock convulsion stimulation device for small animals (UgoBasile), and the presence or absence of induced tonic extension convulsions of the hind limbs was observed. In the above test, it can be confirmed that tonic extension convulsions of the hind limbs are induced in all animals in the vehicle-administered group, whereas the onset of convulsions is suppressed in the test compound-administered group.

[0202] [Test Example 4] Subcutaneous injection pentylenetetrazole model This test is a test for evaluating the anticonvulsant effect of a compound, similar to Test Example 3. The animal model used in this test has a phenotype different from that of Test Example 3, that is, a phenotype of generalized absence seizures or myoclonic seizures. The test compound was suspended in 5% gum arabic / distilled water (w / v) and administered orally at a dose of 30 mg / kg to male ICR mice (Japan SLC Co., Ltd., 5-6 weeks old, 10 mice per group). One hour later, 85 mg / kg of pentylenetetrazole dissolved in saline was administered subcutaneously, and the presence or absence of clonic convulsions was observed for 30 minutes. In the above test, it can be confirmed that clonic convulsions were induced in all animals in the vehicle-administered group, whereas the onset of convulsions was suppressed in the test compound-administered group.

[0203] As described above, the compound of the present invention shows anticonvulsant activity in all of a number of model animals used for evaluating antiepileptic drugs, and is therefore useful as an antiepileptic drug exhibiting a broad therapeutic spectrum (a compound for preventing and / or treating seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures, and status epilepticus). Furthermore, the compound of the present invention is also useful as a compound for diagnosing diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures, and status epilepticus).

Claims

1. Formula I: [In the formula, D is or C optionally substituted with halogen 1-6 is alkyl; Ring A is benzene, pyridine, indole or indazole; Ring B is pyrimidine, pyridazine, pyridine, pyrazole, benzene or naphthalene, wherein (i) when ring B is pyrimidine, ring C is selected from the following unsaturated rings and their oxides, dioxides (excluding pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione) and rings in which some or all of the unsaturated bonds in the ring have been reduced with hydrogen; (a) a 3- to 8-membered monocyclic unsaturated heterocycle containing only 1 to 4 nitrogen atoms as ring-constituting heteroatoms; (b) a 7- to 15-membered bicyclic or tricyclic unsaturated heterocycle containing 1 to 5 nitrogen atoms as the only ring-constituting heteroatoms; (c) a 7- to 12-membered bicyclic unsaturated heterocycle containing only 1 to 3 oxygen atoms as ring-constituting heteroatoms; (d) a 3- to 8-membered monocyclic unsaturated heterocycle containing one or two oxygen atoms and one to three nitrogen atoms as ring-constituting heteroatoms; (e) a 7- to 12-membered bicyclic unsaturated heterocycle containing one or two sulfur atoms and one to three nitrogen atoms as ring-constituting heteroatoms; and (f) 3- to 8-membered monocyclic unsaturated hydrocarbon ring; (ii) when ring B is pyridazine, pyridine, pyrazole, benzene or naphthalene, ring C is pyrimidine-2,4-dione or dihydropyrimidine-2,4-dione; R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -CN or -SF 5 and R 2 is a halogen, C 1-6 Alkyl, -OC 1-6 is alkyl; R 3 is halogen, halogen or -OC 1-6 C optionally substituted with alkyl 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -C 1-6 Alkyl-OH, -OH, -CN, -CONH 2 or -NH 2 and L is a bond, C 1-6 alkylene, -O- or -S-; k is 0, 1, or 2. When k is 2, R 1 each independently represents the same or different substituent; m is 0, 1 or 2, and when m is 2, R 2 each independently represents the same or different substituent; n is 0, 1, or 2, and when n is 2, R 3 each independently represents the same or different substituent; A compound represented by the formula:

2. In formula I, D is and Ring A is benzene or pyridine; Ring B is a pyrimidine; Ring C is selected from the following unsaturated rings, their oxides, dioxides (except for pyrimidine-2,4-dione and dihydropyrimidine-2,4-dione), and rings in which some or all of the unsaturated bonds in the ring have been reduced with hydrogen; Pyridine, Pyridazine, Pyrimidine, Indore, Pyrrolopyridine, Indazole, Benzimidazole, Pyrazolopyridines, Imidazopyridine, Imidazopyrazines, imidazopyridazine, Triazolopyridines, Pyrazolopyrimidines, Imidazopyrimidines, Triazolopyrimidines, Quinoline, Isoquinoline, Naphthyridine, Quinazoline, Quinoxaline, Benzodioxole, Oxazine, oxazepine, benzothiazole, benzene; R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 alkyl or -CN; R 2 -OC 1-6 is alkyl; R 3 is halogen, halogen or -OC 1-6 C optionally substituted with alkyl 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -C 1-6 Alkyl-OH, -OH, -CN, -CONH 2 or -NH 2 and L is -O-; k is 0, 1, or 2. When k is 2, R 1 each independently represents the same or different substituent; m is 0 or 1; n is 0, 1, or 2, and when n is 2, R 3 The compound or salt thereof according to claim 1 , wherein each independently represents the same or different substituent.

3. In formula I, ring C is selected from the following unsaturated rings and their oxides and rings in which some or all of the unsaturated bonds in the rings have been reduced with hydrogen: Pyridine, Pyridazine, Pyrrolopyridine, Indazole, Pyrazolopyridines, Imidazopyridine, Imidazopyrazines, imidazopyridazine, Pyrazolopyrimidines, Triazolopyrimidines, Quinoline, Isoquinoline, Naphthyridine, Quinoxaline, benzene; R 1 is halogen or C optionally substituted with halogen 1-6 is alkyl; R 3 C may be substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -OH, -CONH 2 or -NH 2 and L is -O-; k and n are 0 or 1; The compound or salt thereof according to claim 2, wherein m is 0.

4. In formula I, ring C is selected from the following unsaturated rings and their oxides and rings in which some or all of the unsaturated bonds in the rings have been reduced with hydrogen: Pyridine, Pyridazine, Pyrazolopyridines, Imidazopyridine; R 3 is -OH or -NH 2 and L is -O-; k and m are 0; The compound or salt thereof according to claim 3, wherein n is 0 or 1.

5. In formula I, D is or C optionally substituted with halogen 1-6 is alkyl; Ring A is benzene or pyridine; Ring B is pyridazine, pyridine, pyrazole, benzene or naphthalene; Ring C is pyrimidine-2,4-dione or dihydropyrimidine-2,4-dione; R 1 is halogen, optionally substituted with halogen 1-6 -OC optionally substituted with alkyl or halogen 1-6 Alkyl, -CN or -SF 5 and R 2 is a halogen, C 1-6 Alkyl, -OC 1-6 is alkyl; R 3 is C 1-6 is alkyl; L is a bond, C 1-6 alkylene, -O- or -S-; k is 0, 1, or 2. When k is 2, R 1 each independently represents the same or different substituent; m is 0, 1 or 2, and when m is 2, R 2 each independently represents the same or different substituent; n is 0, 1, or 2, and when n is 2, R 3 The compound or salt thereof according to claim 1 , wherein each independently represents the same or different substituent.

6. In formula I, ring A is benzene; Ring B is benzene, pyridine, or pyridazine; Ring C is dihydropyrimidine-2,4-dione; R 1 is a halogen; L is -O-; k is 0 or 1; The compound or salt thereof according to claim 5 , wherein m and n are 0.

7. A compound selected from the group consisting of the following compounds or a salt thereof.

8. The compound or salt thereof according to claim 7, selected from the group consisting of the following compounds:

9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a salt thereof as an active ingredient, and a pharma- ceutically acceptable carrier or excipient.

10. 9. A therapeutic, preventive and / or diagnostic agent for seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising the compound according to any one of claims 1 to 8 or a salt thereof.

11. Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), and motor seizures in generalized seizures (tonic-clonic, clonic, tonic-clonic ...

11. The therapeutic, preventive and / or diagnostic agent according to claim 10, wherein the seizures are selected from motor seizures (including tonic seizures, myoclonic seizures, myoclonic tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and nonmotor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures (including tonic-clonic seizures and epileptic spasms) and nonmotor seizures (including behavioral arrest seizures) in seizures of unknown onset.

12. Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, unilateral convulsions, hemiplegia, 11. The therapeutic, preventive and / or diagnostic agent according to claim 10, which is selected from epilepsy syndromes, mesial temporal lobe epilepsy syndromes, epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disorders, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), congenital malformations, congenital metabolic disorders (e.g., phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.), and congenital genetic disorders (Rett syndrome, Angelman syndrome, 5p-syndrome, 4p-syndrome, Down syndrome, etc.).

13. A pharmaceutical composition for treating, preventing and / or diagnosing seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus seizures), comprising the compound according to any one of claims 1 to 8 or a salt thereof as an active ingredient.

14. Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), motor seizures in generalized seizures (tonic-clonic, The composition of claim 13, wherein the seizures are selected from motor seizures (including tonic-clonic seizures, tonic seizures, myoclonic-tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and non-motor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures (including tonic-clonic seizures and epileptic spasms) and non-motor seizures (including behavioral arrest seizures) in seizures of unknown onset.

15. Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, and unilateral convulsions. The composition according to claim 13, which is selected from hemiplegia epilepsy syndrome, mesial temporal lobe epilepsy syndrome, epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disorders, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), congenital malformations, congenital metabolic disorders (e.g., phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.), and congenital genetic abnormalities (Rett syndrome, Angelman syndrome, 5p-syndrome, 4p-syndrome, Down syndrome, etc.).

16. A method for treating, preventing and / or diagnosing seizures in diseases accompanied by epileptic seizures or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus), comprising administering to a human an effective amount of a compound according to any one of claims 1 to 8 or a salt thereof.

17. Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), motor seizures in generalized seizures (tonic-clonic, 17. The method of claim 16, wherein the seizures are selected from: non-motor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures (including tonic-clonic seizures and epileptic spasms) and non-motor seizures (including behavioral arrest seizures) in seizures of unknown onset.

18. Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, and unilateral convulsions.

17. The method of claim 16, wherein the epilepsy is selected from epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disease, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), congenital malformations, congenital metabolic disorders (e.g., phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.), and congenital genetic abnormalities (Rett syndrome, Angelman syndrome, 5p-syndrome, 4p-syndrome, Down syndrome, etc.).

19. 9. The compound or salt thereof according to any one of claims 1 to 8 for use in the treatment, prevention and / or diagnosis of seizures in diseases accompanied by epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus).

20. Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), and motor seizures in generalized seizures (tonic-clonic, clonic-clonic, and tonic-clonic seizures).

20. The compound or salt thereof according to claim 19, selected from motor seizures (including typical absence seizures, tonic seizures, myoclonic seizures, myoclonic tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and nonmotor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures (including tonic-clonic seizures and epileptic spasms) and nonmotor seizures (including behavioral arrest seizures) in seizures of unknown onset.

21. Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, unilateral convulsions, unilateral convulsions, 20. The compound or salt thereof according to claim 19, which is selected from paralysis-epilepsy syndrome, mesial temporal lobe epilepsy syndrome, epilepsy attributable to structural or metabolic causes (post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disease, epilepsy associated with brain tumor, epilepsy associated with neurodegenerative disease, epilepsy associated with autoimmune disease, etc.), congenital malformation, congenital metabolic disorder (e.g., phenylketonuria, mitochondrial disease, lysosomal disease, Sturge-Weber syndrome, etc.), and congenital genetic abnormality (Rett syndrome, Angelman syndrome, 5p-syndrome, 4p-syndrome, Down syndrome, etc.).

22. Use of the compound or salt thereof according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment, prevention and / or diagnosis of seizures in diseases accompanied by epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures and status epilepticus).

23. Epileptic seizures include focal seizures (sometimes called partial seizures) with motor onset (including automatisms, atonic seizures, clonic seizures, epileptic spasms, hyperkinetic seizures, myoclonic seizures, and tonic seizures) and non-motor onset seizures (including autonomic, behavioral arrest, cognitive, affective, and perceptual seizures), focal seizures progressing to bilateral tonic-clonic seizures (secondary generalization of partial seizures), motor seizures in generalized seizures (tonic-clonic, 23. The use according to claim 22, wherein the seizures are selected from motor seizures (including tonic-clonic seizures, tonic seizures, myoclonic-tonic-clonic seizures, myoclonic atonic seizures, atonic seizures and epileptic spasms) and non-motor seizures (including typical absence seizures, atypical absence seizures, myoclonic absence seizures and lid myoclonic seizures); motor seizures (including tonic-clonic seizures and epileptic spasms) and non-motor seizures (including behavioral arrest seizures) in seizures of unknown onset.

24. Diseases accompanied by epileptic seizures or convulsive seizures include Dravet syndrome, Lennox-Gastaut syndrome, West syndrome (infantile spasms), Ohtahara syndrome, Doose syndrome, Landau-Kleffner syndrome, Rasmussen syndrome, Aicardi syndrome, Panayiotopoulos syndrome, Kojewnikow syndrome, Tassinari syndrome, Geschwind syndrome, and unilateral convulsions.

23. The use according to claim 22, wherein the epilepsy is selected from epilepsy due to structural or metabolic causes (e.g., post-stroke epilepsy, traumatic epilepsy, infectious epilepsy, epilepsy associated with cerebrovascular disorders, epilepsy associated with brain tumors, epilepsy associated with neurodegenerative diseases, epilepsy associated with autoimmune diseases, etc.), congenital malformations, congenital metabolic disorders (e.g., phenylketonuria, mitochondrial diseases, lysosomal diseases, Sturge-Weber syndrome, etc.), and congenital genetic disorders (e.g., Rett syndrome, Angelman syndrome, 5p-syndrome, 4p-syndrome, Down syndrome, etc.).

Citation Information

Patent Citations

  • Novel pyrimidine and triazine hepcidin antagonists

    JP2013503833A

  • Imidazolidinedione derivatives

    JP2013513564A

  • Heterocyclic compounds for treating epilepsy

    JP7539377B2

  • Novel Pyrimidine- And Triazine-Hepcidine Antagonists

    US20120202806A1

  • Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultura / horticultural bactericides

    WO2000029404A1